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ABSTRACT OF DISSERTATION 
 
 
ROLE OF GROUP X SECRETORY PHOSPHOLIPASE A2 IN MURINE 
ADIPOCYTES 
 
 
 
The secretory phospholipase A2 (sPLA2) family is a group of enzymes that 
catalyze the hydrolysis of glycerophospholipids at the sn-2 position, generating free 
fatty acids and lysophospholipids. The sPLA2 family has been implicated in various 
physiological and pathological activities. Eleven sPLA2’s have been identified in 
mammals, and the function of each isoform likely reflects its tissue distribution and 
substrate specificity. Studies in vitro indicate that Group X (GX) sPLA2 potently 
releases arachidonic acid (AA) and lysophosphatidylcholine from mammalian cell 
membranes. Interestingly, some of the biological effects mediated by GX sPLA2 in 
vitro are independent of its catalytic activity. Despite a wealth of in vitro data, the in 
vivo function of GX sPLA2 still remains to be elucidated. 
 
In order to define the function of GX sPLA2 in vivo, our laboratory recently 
generated C57BL/6 mice with targeted deletion of GX sPLA2 (GX-/- mice). When fed 
a normal rodent diet, GX-/- mice gained significantly more weight and had increased 
adiposity compared to GX+/+ mice, which was not attributable to alterations in food 
consumption or energy expenditure. When treated with adipogenic stimuli ex vivo, 
stromal vascular cells isolated from adipose tissue of GX-/- mice accumulated 
significantly more (20%) triglyceride compared to cells from GX+/+ mice. Conversely, 
overexpression of GX sPLA2, but not catalytically inactive GX sPLA2, resulted in a 
significant 50% reduction in triglyceride accumulation in OP9 adipocytes. The 
induction of adipogenic genes, including PPAR-γ, SREBP-1c, SCD-1 and FAS was 
also significantly blunted by 50-80% in OP9 cells overexpressing GX sPLA2.  
Activation of the liver X receptor (LXR), a nuclear receptor known to upregulate 
adipogenic gene expression, was suppressed in 3T3-L1 and OP9 cells when GX 
sPLA2 was overexpressed. Thus, hydrolytic products generated by GX sPLA2 
negatively regulate adipogenesis, possibly by suppressing LXR activation.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 The secretory phospholipase A2 (sPLA2) family 
1.1.1 General properties of sPLA2 
  The sPLA2 family is a group of enzymes that catalyzes the hydrolysis of 
phospholipids on the sn-2 position, producing free fatty acid and 
lysophospholipids (Fig 1.1). Eleven isoforms have been identified in mammals, 
which were defined based on the number and positions of disulfide bonds and 
their molecular structures [1]. These isoforms differ in their tissue distribution and 
substrate specificities [2]. The first cloned sPLA2 was Group (G) IB sPLA2, which 
was initially isolated from the pancreas[3]; followed by the identification of a non-
pancreatic sPLA2, GIIA sPLA2 from the synovial fluid[4] and blood platelets [5] of 
rheumatoid arthritic patients. Later, several novel sPLA2s were identified by 
screening the cDNA database. Until now, the cloned human sPLA2s are GIB, 
GIIA, GIID, GIIE, GIIF, GIII, GV, GX and GXIIA, along with GXIIB PLA2-like 
protein that lacks catalytic activity. The mouse and human sPLA2 are highly 
conserved [6-7]. The sPLA2 isoforms are characterized by low molecular weight 
(13~18 kDa), the requirement for histidine in the active site, and the requirement 
of millimolar range of Ca2+ for their catalytic activities. Each isoform has 6-8 
disulfide bonds, which stabilize their structure.  
  The function of each isoforms may possibly reflect their tissue distribution, 
hydrolytic activity and substrate preferences [8]. GIB sPLA2, with its initial 
discovery in the pancreas, was found to play a major role in phospholipid 
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digestion [9]. After prolonged high fat feeding, GIB-/- mice were found to have 
reduced fat absorption and be resistant to obesity and diabetes [10]. Interestingly, 
GIB sPLA2 may also participate in insulin secretion in pancreatic islet β cells [11]. 
In addition, GIB sPLA2 was also found to be expressed in other tissues, such as 
gastric mucosa and lung [12], which was found to mediate signaling through 
interacting with sPLA2 receptor [13]. Moreover, the hydrolytic activities of sPLA2 
towards cell and bacterial membranes were also found to be associated with 
defense against bacterial and other pathogens [14-15]. The antimicrobial function 
is best characterized in GIIA sPLA2, which strongly hydrolyzes the membranes of 
gram positive bacteria [16], as well as gram negative bacteria upon penetration 
of the lipopolysaccharide (LPS) coat [17]. The antimicrobial effect of sPLA2 also 
highly depends on its access to the bacterial cell membrane, which is determined 
by bacterial cell membrane structure and surface charge of sPLA2 molecules [18-
19]. In addition, some sPLA2 may also regulate host defense against viruses and 
parasites. Venom sPLA2 [20] and human GX sPLA2 [21] were shown to inhibit 
infection by human immunodeficiency virus (HIV). GV and GX sPLA2 were found 
to prevent adenoviral infection in mammalian cells by retarding the entry of 
adenovirus into the endosomes [22].  
The analysis of interfacial binding study has provided a possible 
explanation for the diverse physiological functions of the sPLA2 isoforms. For 
example, human GIIA sPLA2 has a much higher binding affinity to artifical 
membrane containing anionic phospholipids, such as phosphatidylglycerol (PG) 
and phosphatidylserine (PS), than membranes with mainly neutral 
phosphatidylcholine (PC), which is the most abundant phospholipid on 
3 
 
mammalian cell membrane[23]. Therefore, PG-enriched membranes of gram 
positive bacterial are susceptible to GIIA sPLA2 mediated degradation, but 
mammalian cell membranes are relatively more resistant [14, 19]. In addition to 
enzymatic hydrolysis, GIIA sPLA2 was shown to stimulate neutrophils to release 
bactericidal enzymes [24]. GV sPLA2 was found to kill ingested bacteria through 
its regulation of eicosanoid synthesis, which is involved in phagocytosis [25]. 
 
1.1.2 sPLA2 and inflammation 
    The detection of sPLA2 activity in the plasma and biological fluids of patients 
with systemic inflammation, autoimmune disease and allergic diseases has 
revealed their potential role in inflammatory and immune responses [26]. In 
rodents, GIIA, GIIC, GIIE, GIIF and GV sPLA2 were detected in murine mast cells 
[27]. GV sPLA2 and GX sPLA2 were detected in murine macrophages [28-29]. 
GIIA sPLA2 is an acute-phase protein, with mRNA expression highly upregulated 
during inflammation, whereas the expression of GX sPLA2 is not significantly 
regulated by inflammatory stimuli [30]. Increased plasma GIIA sPLA2 mass and 
activity was found to be an independent risk factor for cardiovascular events [31-
32]. GV sPLA2 and GX sPLA2 are expressed in epithelial cells of normal [33] and 
inflamed lungs as well as interstitial and alveolar macrophages [34].  
  The biological effects mediated by sPLA2 are largely related to their 
hydrolytic activities. GXIA, GIIIA, GV and GX sPLA2, by binding to the outer layer 
of mammalian cells, effectively hydrolyze membrane phospholipids, and thus 
generate abundant amounts of arachidonic acid (AA) [35-36]. AA is known to be 
the precursor for various signaling lipid mediators involved in numerous 
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pathophysiological conditions, such as prostanoids and leukotrienes [37-38]. 
Cells transfected with human GIIA and GX sPLA2 result in significantly enhanced 
AA release, and this may involve the synergizing effect  of cytosolic 
phospholipase A2 (cPLA2)-α [39]. Interestingly, this study also suggested that 
sPLA2 may hydrolyze intracellular targets during secretion. It was supported by 
the finding that a cell-impermeable inhibitor Me-indoxam could only partially block 
the increased release of AA by GIIA or GX sPLA2 overexpression. It was also 
supported by the evidence that exogenous addition of GIIA sPLA2 much less 
effectively induced AA release, compared to the constitutive overexpression of 
the enzyme.  
 
1.1.3 sPLA2 receptor  
   The biological effect of sPLA2 was also found to be mediated by 
interaction with sPLA2 receptors. The discovery of sPLA2 receptor initially started 
with the identification of the receptor that recognizes neurotoxic snake venom 
sPLA2 (OS2), which was isolated from the venom of the Australian taipan snake 
Oxyuranus scutellatus scutellatus. Compared to other tissues, brain express 
higher levels of this receptor, which was therefore, designated the N-type 
(neuronal-type) receptor [40]. It has several protein subunits of 36–51 kDa and 
85 kDa [41]. Several neurotoxic venom sPLA2 showed high binding affinity to N-
type receptor, whereas the affinity for non-toxic venom sPLA2 was much weaker. 
A correlation (r = 0.80) was found between sPLA2 toxicity and affinity to N-type 
receptor [41]. This study suggested that the binding of neurotoxic sPLA2 to the N-
type receptor may play a crucial role in their neurotoxic effect. Later, another type 
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of OS2 receptor, with a single 180-kDa subunit [42], was identified in rabbit 
skeletal muscle, thereby named the M-type (muscle type) receptor. In mouse, 
several mammalian sPLA2s were found to be natural ligands with different 
binding affinity for M-type receptor, including GIB, GIIA and GX sPLA2 [43]. The 
interaction between sPLA2 proteins and M-type receptors has been shown to 
mediate at least two biological functions: 1) a negative regulator of sPLA2 by 
inhibiting sPLA2 activity and /or clearing sPLA2 molecules from the extracellular 
region [44]; 2) inducing intracellular signaling through the interaction between 
sPLA2 and M-type receptor, such as ERK1/2 phosphorylation [45].  
 
1.1.4 sPLA2 inhibitors 
A number of sPLA2 inhibitors have been developed as pharmaceutical 
products and laboratory reagents (Fig 1.2). The first reported compounds were 
substituted indoles and indolizines developed by Lilly and Shionogi, which are 
the most potent sPLA2 inhibitors [46-49], such as indolizine Indoxam, Me-
Indoxam and LY315920, etc. The development of these inhibitors was based on 
the structure-guided binding potency. Their pharmoacokinetic profiles have 
indicated their drug potential. Despite some selectivity for certain sPLA2 isoforms, 
none of the compounds developed to date exhibit complete specificity to any of 
the sPLA2 isoforms.  
Several animal studies have been carried out to test the effect of sPLA2 
inhibitors. Varespladib methyl (1-H-indole-3-glyoxamide; A-002) inhibits GIIA, GV 
and GX sPLA2 [50]. In apoE-/- mice, A-002 treatment was found to protect against 
atherosclerosis development [51]. In an ischemia-reperfusion injury model in 
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C57BL/6 mice, treatment with LY374388 reduced myocardial infarction and 
improved left ventricular ejection fraction. In addition to blocking sPLA2 activity, 
sPLA2 inhibition was also found to decrease their binding affinity to M-type 
receptor [7].  
Several clinical trials were designed to investigate the pharmacological 
effects of sPLA2 inhibition in patients with coronary heart dieases (CHD). The 
effect of A-002 was evaluated in Phospholipase Levels and Serological Markers 
of Atherosclerosis (PLASMA) trial (NCT00455546) [52], a Phase II, randomized, 
double-blinded and placebo controlled trial with four doses (50, 100, 250 or 500 
mg) of A-002 in 393 patients with CHD. In this study, after 8 weeks of treatment, 
mean plasma GIIA sPLA2 level, oxidized LDL and CRP concentration were 
decreased. The adverse effect was only observed in one of the patients with the 
highest dose (500 mg). In PLASMA II trial (NCT00525954), in addition to the 
measurement in PLASMA, inflammatory biomarkers, lipid levels and lipoprotein 
profiles were also assessed in 135 patients with stable CHD. This study has been 
completed with results to be published.   
 
 
1.1.5 Unique features of GX sPLA2 
   GX sPLA2 is initially secreted from cells as an inactive pre-pro-peptide, 
which undergoes proteolytic cleavage to become fully active [53]. However, the 
mechanism regulating the proteolytic cleavage remains to be investigated. 
Compared to other isoforms, GX sPLA2 has the highest catalytic activity towards 
phosphatidylcholine [35]. Studies in vitro indicate that hydrolysis by GX sPLA2 
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produces the most potent release of AA and lysophosphatidylcholine [29, 54]. A 
tryptophan residue on the interfacial binding surface of human GX sPLA2 
increases its binding affinity to PC enriched membrane, which may explain why 
GX sPLA2 has the highest hydrolytic activity towards mammalian cell membranes 
[23]. Interestingly, a study using lipoprotein substrates has shown the preferential 
release of AA from PCs by GX sPLA2 [55], which could further explain the high 
capacity for GX sPLA2 mediated AA release. Some of the biological features of 
GX sPLA2 were reported to be independent of its catalytic activities [45]. 
Compared to other sPLA2 isoforms, GX sPLA2 has the highest affinity towards 
the M-type receptor [43]. Unlike some isoforms, such as GIIA and GV sPLA2, GX 
sPLA2 does not bind to heparan sulphate proteoglycanes [56]. It has been 
suggested that secreted GX sPLA2 may be taken up by cells, possibly by binding 
the M-type receptor [44-45, 57]. This endocytosis process was shown to play a 
role in GX sPLA2 intracellular degradation, and thus may provide a mechanism to 
decrease its enzymatic activity [58]. GX sPLA2 is a secretory enzyme and 
originally, its activity was assumed to be targeted towards extracellular sites, 
such as phospholipids on the outer leaflet of plasma membrane, lipoprotein 
particles, lung surfactant, and bacteria membranes. (reviewed in [2]). However, a 
study has indicated that GX sPLA2 may hydrolyze intracellular targets before the 
enzyme is secreted [39]. 
Despite a wealth of data about GX sPLA2 in vitro, information about the 
physiological role of GX sPLA2 in vivo remains limited. It was shown that GX 
sPLA2 is widely expressed in various tissues and organs in the mouse, with the 
highest expression level in testis and small intestine (Fig 1.3). The best 
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characterized function for GX sPLA2 in vivo is its modulation of allergen-induced 
airway inflammation [59]. The lungs of GX sPLA2 deficient mice exhibited 
significant protection against ovalbumin-induced CD4+, CD8+ T cells and 
eosinophils infiltration, goblet cell metaplasia, smooth muscle cell layer 
thickening and subepithelial fibrosis. This protective effect may be attributed to 
the reduction in the synthesis of eicosanoids, AA metabolites, in the absence of 
GX sPLA2, since leukotrienes and prostaglandins are known mediators of asthma 
pathogenesis [60-61]. GX sPLA2 -/- mice were also found to have significantly 
decreased myocardial infarct size and reduced myocardial myeloperoxidase 
activity, which was proposed to be due to suppressed neutrophil cytotoxic 
activities [62]. GX sPLA2 transgenic (Tg) mouse neonates showed minimal 
respiratory phenotype, with normal alveolar architecture and surfactant 
composition. In contrast, GV sPLA2 Tg mice had severe lung atelectasis with 
thickened alveolar walls and narrow air spaces [63]. The authors presented 
evidence that the lack of phenotype in GX sPLA2 transgenic mice is due to the 
fact that this isoform mostly remains an inactive zymosan under physiological 
conditions, and the proteolytic cleavage was likely to be activated during 
inflammation. Another study using Tg mice with macrophage specific GX sPLA2 
overexpression indicated that the Tg mice were neonatally lethal due to severe 
lung pathology, with massive granulocyte and surfactant-laden macropage 
infiltration [64]. They have also shown that macrophage cell line RAW264.7 with 
overexpression of active GX sPLA2 had signficantly promoted foam cell formation, 
with incubation of both native LDL and oxidized LDL. This study has provided 
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evidence that macrophage expressing GX sPLA2 plays an important role in 
inflammatory responses and pathological conditions in lung.  
 
1.2 Obesity and adipocyte biology 
1.2.1 Obesity epidemic 
In the past few decades, obesity has become an epidemic disease with 
rapidly growing prevalence around the world, especially in Western countries. 
The World Health Organization (WHO) defines "overweight" as a BMI ≥ 25 kg/m2, 
and "obesity" as a BMI ≥ 30 kg/m2. The WHO’s 2005 reports indicate that globally, 
approximately 1.6 billion adults (age 15+) were overweight; and at least 400 
million adults were obese. Presently, 22 million children under five are estimated 
to be overweight. In developed countries, obesity was estimated to account for at 
least 2-6% of total health care costs. Obesity highly increases the risk for many 
diseases, including type II diabetes, hypertension, dyslipidemia, nonalcoholic 
fatty liver disease (NAFLD), reduced fertility, cancer, obstructive sleep apnea, 
osteoarthritis and cardiovascular complications (reviewed in [65]). ~80% of 
diabetes cases were reported to be associated with weight gain (International 
Diabetes Federation 2003, Diabetes Atlas). Clinical studies have indicated 
increasing incidence of death for adolescents and adults up to 75 years of age 
due to obesity related cardiovascular diseases [66]. Moreover, it was also shown 
that BMI over 30 is associated with reduced life expectancy, regardless of sex, 
age or ethnicity [67].  
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1.2.2 Adipose tissue 
Obesity is defined as “abnormal or excessive fat accumulation that may 
impair health” (WHO). Adipose tissues can be subdivided into brown adipose 
tissue (BAT) and white adipose tissue (WAT), based on the cell morphology and 
functions [68]. The major function for BAT is nonshivering thermogenesis through 
the uncoupling of oxidative phosphorylaiton, which converts energy into heat [69]. 
This requires abundant number of mitochondria in BAT, shown as brown color. 
WAT is specialized for storage and mobilization of energy in the form of 
triglyceride (TG), which can be further categorized as visceral and subcutaneous 
adipose depot. Adipose tissue is heterogenous, in which the major cell type is 
mature, lipid-laden adipocytes. In addition, there are also other cell types such as 
macrophages, preadipocytes, fibroblasts, endothelial cells and vascular cells, 
which are collectively defined as the stromal vascular fraction (SVF) [70]. The 
primary function for WAT is lipid storage / mobilization. Dietary excess leads to 
lipid accumulation in adipocytes, brought about by adipocyte hypertrophy and/or 
hyperplasia. The balance between lipid storage and mobilization is critical, since 
chronic exposure of nonadipose cells to elevated plasma free fatty acid (FFA) is 
associated with higher risk for insulin resistance[71-72].  
1.2.2.1 Adipocyte hyperplasia and hypertrophy 
 The expansion of white adipose tissue (WAT) is from two processes, the 
conversion of precursor cells into differentiated adipocytes (hyperplasia), and the 
size increase of individual adipocyte due to increased storage of TG 
(hypertrophy).  In humans, total body fat mass is determined by both adipocyte 
number and adipocyte size, although the total number of adipocytes increases 
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only in childhood and adolescence [73]. Despite an apparently fixed number of 
adipocytes, the adipocyte population nevertheless appears to undergo a 
remarkable rate of turnover in adults.  According to one estimate, approximately 
10% of fat cells are renewed every year in adults, regardless of the size of the fat 
depot [73]. Thus, in order to maintain a constant number of adipocytes, feedback 
mechanisms is needed to regulate adipogenesis and adipocyte hypertrophy 
when energy balance is perturbed.  In obesity, the failure to appropriately 
respond to the need to store excess energy in the form of TG may lead to 
metabolic disorders [74-75].  
1.2.2.2 Lipid homeostasis in adipose tissue 
1.2.2.2.1 TG storage 
A number of genes participate in TG biosynthesis in adipocytes, with the 
best characterized being glycerol-3-phosphate acyltransferase (GPAT), 1-
acylglycerol-3-phosphate acyltransferase (AGPAT), phosphatidate phosphatase 
(PAP or lipin) and diacylglycerol transferase (DGAT). 
The conversion of glycerol 3-phosphate and acyl-CoA to 1-acylglycerol-3-
phosphate (lysophosphatidate, LPA), mediated by GPAT, is the first step of TG 
synthesis in adipocytes [76]. The following acylation step is mediated by AGPAT, 
which converts LPA to phosphatidate (PA) [77]. In the 10 identified AGPATs, in 
vitro assay has shown that AGPAT2 has the most robust activity [78]. AGPAT2 
silencing in OP9 adipocytes led to reduced induction of adipogenic genes, such 
as PPARγ and CCAAT/enhancer binding protein β (CEBPβ), along with reduced 
TG accumulation [79]. AGPAT2-/- mice is a mouse model of lipodystrophy, with 
impaired adipose tissue development, severe hepatic steatosis and insulin 
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resistance [78]. PA is then dephosphorylated by PAP (Lipin) to generate DAG, 
substrates for the synthesis of TG and phospholipids (reviewed in [80]). In 3 
identified isoforms, Lipin1 was characterized in a model of fatty liver dystrophy 
mice (fld mice). fld mice developed lipodystrophy, fatty liver, hypertriglyceridemia 
and insulin resistance [81]. Primary mouse embryonic fibroblasts (MEF) from fld 
mice showed significantly reduced adipogenic gene expression [82]. DGAT 
catalyzes the conversion from DAG to TG by addition of the third fatty acyl-CoA. 
Two DGAT isoforms have been identified, DGAT1 [83] and DGAT2 [84]. DGAT1-/- 
mice have normal weight with normal rodent feeding, however, are protected 
from diet induced obesity [85], without any change in food consumption [86]. In 
contrast, DGAT2-/- mice die only a few hours after birth, with 64% reduction in 
plasma TG, 80% in FFA and 60% in glucose [87].  
1.2.2.2.2 Lipolysis 
During fasting, the hydrolysis of TG produces glycerol and FFA, vital 
sources of cellular energy. Two major enzymes, hormone sensitive lipase (HSL) 
and adipose tissue triglyceride lipase (ATGL) are responsible for the bulk of TG 
hydrolysis (>95%) in murine adipocytes [88-89]. HSL is the first discovered 
enzyme that mediates lipid mobilization from adipocytes [89]. By binding the β-
adrenergic receptor, catecholamines lead to increased intracellular levels of 
adenosine 3’, 5’-monophosphsphate (cAMP), thereby activating protein kinase A 
(PKA). PKA can phosphorylate HSL, which induces the activation and 
translocation of HSL to the surface of lipid droplets, thereby promoting lipolysis 
[90]. Studies in HSL-/- mice led to the discovery of other TG hydrolases, most 
importantly, ATGL[91-93]. ATGL-/- mice exhibited reduced β-adrenergic receptor 
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stimulated TG hydrolysis [94]. ATGL catalyzes the initial step in TG hydrolysis 
[93], whereas HSL favors DAG [95].  
In addition to HSL and ATGL, lipid droplet associated proteins, including 
the PAT family (perilipin, adipophilin or ADRP, Tip47), CGI-58 and FSP27 also 
play a role in regulating lipolysis [96-98]. Perilipin A is the most abundant protein 
on the surface of lipid droplets [99-100], and is required for the recruitment of 
HSL to lipid droplets [101]. The phosphorylation of perilipin A is not required for 
the translocation of HSL [102]; however, it contributes to the fragmentation of 
large lipid droplets during lipolytic stimulation [103]. The activity of ATGL is 
regulated by PKA-stimulated phosphorylation of perilipin A, with the coactivator 
CGI-58[97, 104]. Under basal conditions, CGI-58 remains associated with lipid 
droplets through an interaction with perilipin, whereas upon elevation of cAMP, 
CGI-58 dissociates from perilipin and approaches the proximity of ATGL [105-
106]. Adipocytes lacking FSP27 form multilocular lipid droplets, which have 
increased basal lipolysis (Nishino 2008). It has been suggested that the total 
surface area of lipid droplets may be increased by the multilocular lipid droplet, 
thereby increasing the access of lipases to the lipid core and promoting lipolysis.  
1.2.2.3 Adipose tissue as an endocrine organ 
Obesity is found to be chronic, low-grade inflammation [107], 
characterized by increased macrophage accumulation in adipose tissues and 
enhanced cytokine production in the obese individuals. Adipose tissue used to be 
considered as an inert storage organ, which stores excess calorie in the form of 
TG. However, it has been widely accepted that adipose tissue is an important 
endocrine organ [72, 108]. Most of the association between obesity and insulin 
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resistance is generated from visceral fat and ectopic TG accumulation [109].  
Leptin was the first identified fat cell specific hormone acting on 
hypothalamus to control appetite and also some other organs [110]. In addition, 
leptin was also shown to play an important role in immune response and 
inflammation (reviewed in [111]). Later, numerous factors secreted by adipose 
tissues were reported to act either in an autocrine and/or paracrine manner, such 
as resistin, adiponectin, and various cytokines including tumor necrosis factor 
(TNFα), interleukins (such as IL-1β, IL6, IL8 and IL8), and chemoattractant 
proteins (such as monocyte chemotatic protein-1, [MCP-1] and macrophage 
inflammatory protein-1α) [112].  
Another best characterized adipokine is adiponectin. It circulates in the 
blood as various molecular structures, known as low-molecular weight form 
(LMW) and high-molecular weight (HMW) form. Interestingly, although 
adiponectin is an adipocyte specific protein, its circulating level seems to be 
inversely correlated with patients’ adipose mass, but positively correlated with 
insulin sensitivity [113]. Mice or humans treated with insulin sensitizer, PPARγ 
agonists, showed significantly elevated circulating adiponectin [114], which led to 
the statement that the development of diabetes might be associated with the 
gradually decreased adiponectin level.  
Resistin is a protein secreted by adipocytes as well as various other cells, 
including skeletal muscle, pancreatic cells, and mononuclear cells, such as 
macrophages [115]. In contrast to adiponectin, resistin was found to be 
significantly reduced by the treatment of PPARγ agonist, thiazolidinediones 
(TZDs) [116]. This study for the first time demonstrated that mice injected with 
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purified recombinant resistin protein had significantly reduced insulin sensitivity. 
An in vitro study using 3T3-L1 adipocytes showed that resistin treatment reduced 
insulin-mediated glucose uptake by 37%.  
Another aspect in the regulation of insulin sensitivity by adipose tissue 
was shown to be associated with FFA flux (reviewed by [117]). Elevated FFA flux 
and other lipid metabolites, such as DAG, may enhance reactive oxygen species 
production, generate tissue oxidative damage, induce NF-КB signaling and 
compromise insulin signaling [118-120]. Pharmacological inhibition of lipolysis 
was found to have a beneficial effect to reverse insulin resistance [118, 121]. 
Elevated FFA flux from adipose tissue may lead to β cell dysfunction and 
impaired insulin secretion, which clearly further exacerbates type II diabetes 
[122].  
Taken together, the role of adipose tissue in systemic inflammation has 
been well established in the past decades. Adipose tissue dysfunction, including 
the secretion of proinflammatory cytokines, adipokines, and unbalanced TG 
storage /mobilization, was shown to directly increase the risk of diabetes and 
cardiovascular complications.  
1.2.3 Adipocyte differentiation 
The differentiation of lipid-laden adipocytes from fibroblast-like 
preadipocytes involves a critically regulated signaling cascade, with the activation 
of a series of transcription factors. Extensive studies have been performed in 
both multipotent and preadipocyte cell lines to investigate the key events that 
occur during adipocyte development. The first process defined as ‘commitment’, 
is the determination of precursor cells to the adipocyte lineage in response to 
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adipogenic stimuli [123]. Following commitment, precursor cells undergo growth 
arrest and mitotic clonal expansion, which leads to changes in chromatin 
structure and the development of an adipocyte phenotype [124]. The master 
regulators are transcription factors CCAAT/enhancer binding proteins (C/EBPs) 
and peroxisome proliferator-activated receptor γ (PPARγ)[125-127]. C/EBPα, β, 
and δ belong to a family of proteins with highly conserved basic-leucine zipper 
residues. C/EBPβ and δ are activated immediately after differentiation is induced 
[128]. Deficiency of either C/EBPβ or δ leads to impaired white adipose tissue 
growth in mice and reduced adipogenesis of MEFs ex vivo [129]. On the contrast, 
C/EBPα was found to be activated by C/EBPβ and δ, through C/EBP regulatory 
element in its promoter [130].  
PPARγ was found to be the key transcription factor induced by adipocyte 
differentiation, which is also induced by C/EBPβ, and δ [131]. PPARγ forms a 
heterodimer with retinoid X receptor (RXR) to regulate transcription of adipocyte 
specific genes by interacting with PPARγ response elements (PPREs) [132-133]. 
Upon activation, PPARγ and C/EBPα were found to positively regulate each 
other’s expression [125]. 3T3-L1 cells with PPARγ knockdown fail to differentiate 
into mature adipocytes, however, it was also shown that PPARγ was not required 
for the maintenance of mature adipocytes [134]. Whole body PPARγ deficient 
mice are embryonic lethal due to placental dysfunction [135]. Another important 
role of PPARγ is to regulate insulin sensitivity. The well-known insulin sensitizer 
thiazolidinedione (TZD) is a high affinity ligand for PPARγ. Mice with adipose 
tissue specific PPARγ deficiency exhibit to severely reduced insulin sensitivity in 
adipose tissue and liver but not in the muscle [136]. 
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Following the activation of the transcription factors listed above, SREBPs 
also play a role in adipogenesis. By screening a rat adipocyte cDNA library, 
adipocyte determination and differentiation-dependent factor 1 (ADD1) was 
cloned, and later found to be homologous to human SREBP-1c [137]. SREBP-1c 
mRNA is induced 24 hours after treatment with differentiation stimuli in 3T3-
F442A and 3T3-L1 cells [138]. Overexpression of SREBP-1c led to enhanced 
adipogenesis, an effect that is PPARγ-dependent. Interestingly, overexpression 
of SREBP-1c in 3T3-L1 cells induces the expression of PPARγ, indicating 
crosstalk between these two factors [139]. In additon to these critical transcription 
factors, a number of extracellular factors, such as Wnt and transforming growth 
factor β (TGFβ), were also found to participate in the regulation of adipocyte 
differentiation (reviewed by [140]).  
Upon the activation of a series of critical transcription factors, preadipocyte 
cells eventually enter the phase of terminal differentiation. In 3T3-L1 cells, this 
process was shown to be associated with the expression of cyclin-dependent 
kinase inhibitors p18, p21 and p27 [141]. During this stage, PPARγ was found to 
inhibit E2F/DP1 DNA-binding activity, thereby leading the cells to withdraw from 
cell cycle [142]. The cells continuously accumulate intracellular lipid and gain 
adipocyte functions by expressing specific genes, including fatty acid transporter 
CD36, fatty acid binding protein (FABP, or aP2), glucose transporter 4 (GLUT4), 
leptin and adiponectin. The differentiated cells exhibit the functions in maintaining 
TG and glucose homeostasis.  
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1.3. Liver X Receptor (LXR) 
1.3.1 General properties of LXRs 
  LXRs were initially discovered through screening a rat liver cDNA library by 
binding to retinoid X receptor (RXR) [143]. Two LXR isoforms were identified in 
mammals, LXRα (NR1H3) and LXRβ (NR1H2), which share ~78% identity in 
amino-acid sequence [144]. LXRα is mainly expressed in steroidogenic tissues, 
such as liver, intestine, kidney, spleen and adipose tissue, pituitary and adrenal 
gland[145], while LXRβ is ubiquitously expressed [146]. The structure of LXRs 
contain an N-terminal ligand-independent activation function domain (AF-1), a 
DNA-binding domain (DBD), a hydrophobic ligand-binding domain (LBD) and a 
C-terminal ligand-dependent activation function domain (AF-2). LXRα has three 
different variants, LXRα1, LXRα2 and LXRα3, generated from alternative 
promoter usage and mRNA splicing [147]. LXRα2, generated by the use of a 
novel promoter and first exon, lacks of the first 45 amino acids of LXRα1. LXRα3, 
generated through alternative recognition of the 3’-splice site in exon 6, lacks 50 
amino acids within the ligand binding domain. The major form in most of the 
tissues is LXRα1 except in testes, in which LXRα2 is predominant. LXRα2 is less 
capable of inducing target transcription, compared to LXRα1; whereas LXRα3 
was found to antagonize the function of the other two isoforms.  
1.3.2 LXRs’ natural ligands and antagonists  
  LXR was initially defined as an orphan receptor without known ligands. 
Later, oxysterols were found to be natural ligands for LXR activation [148-149]. 
The most potent oxysterols to induce LXR activation are 22(R)-
hydroxycholesterol, 20(S)-hydroxycholesterol, 24(S)-hydroxycholesterol and 
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24(S),25-epoxycholesterol [149]. Either LXRα and LXRβ can bind with RXR to 
form heterodimer, which then bind on the promoter region of target genes on liver 
X receptor response element (LXRE) and facilitate transcriptional regulation 
[150-151]. The “ideal” LXRE has two direct repeats of a hexanucleotide 
sequence (AGGTCA) separated by a four base element (DR-4 element). 
However, study in a series of LXR target genes has indicated the existence of 
‘non-ideal’ LXRE, with variant nucleotides. LXRα and LXRβ have similar binding 
affinity to the ideal LXRE, however, their affinity to non-ideal LXRE may be 
different [152] [153]. The heterodimer of LXR / RXR can be independently 
activated by ligands for either LXR or RXR; therefore it was named as permissive 
heterodimer [150]. In the absence of ligands, complexes of corepressors are 
bound to the LXRE, which suppresses the activity of LXR. Upon ligand binding, 
along with the recruitment of coactivator, LXR and RXR form heterodimer and 
translocate to the LXRE region, thereby facilitating transcription of target genes 
[154].  
  In contrast, n-3 and n-6 polyunsaturated fatty acids (PUFAs), such as 
arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and linoleic acid 
were found to be competitive antagonists for LXR [155-156]. There is no such 
effect for saturated fatty acid or minimal effect for monosaturated fatty acid. At 
least two possible pathways were described to be the mechanism by which 
PUFA antagonizes LXR. One possible mechanism is through the competitive 
binding of PUFA on the ligand binding domain of LXR, thereby preventing the 
binding by LXR agonist [156]. The other possible mechanism is through the 
interaction with PPAR. Since PUFAs and their metabolites were found to be the 
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activators of PPARα and PPARγ [157-158], both of which may bind with RXR to 
form heterodimers. This competitive binding may reduce the potential for LXR to 
bind on RXR, thereby reducing LXR signaling. In addition, an intermediate of 
cholesterol synthesis, geranylgeranyl pyrophosphate, was also found to 
antagonize the interaction with of LXRα and LXRβ with nuclear coactivators 
SRC-1, thereby inhibiting LXR activation [159]. 
 
1.3.3 Physiological roles of LXRs 
1.3.3.1 Cholesterol sensor 
  The firstly identified LXR target gene was mouse cholesterol 7α-hydroxylase 
(CYP7A1), which is a rate-limiting enzyme that regulates bile acid synthesis [149]. 
This revealed the potential role of LXRs in cholesterol homeostasis. Interestingly, 
the promoter of human CYP7a1 is not responsive to LXR activation. Later, more 
LXR target genes have been identified, with the best characterized being ATP-
binding cassette transporters A1 (ABCA1) and ABCG1, which play a major role in 
cholesterol efflux [160]. Later, ABCG5 and ABCG8 were also identified as LXR 
target genes [161], which supported the role of LXRs as sterol sensors.  
  In addition to directly targeting the genes that regulate cholesterol efflux, 
LXRs were also found to regulate cholesterol homeostasis by targeting some 
proteins that may influence lipoprotein metabolism. For example, lipoprotein 
lipase (LPL), a key enzyme that regulates the hydrolysis of triglyceride (TG) in 
lipoproteins particles, was found to be a LXR target gene [162]. The role of LXRs 
in cholesterol homeostasis was supported by the studies using genetically 
engineered mice. LXRα-/- mice fed a high-cholesterol diet exhibited 
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hypercholesterolemia and massive increase in hepatic cholesterol, while wild 
type control mice were resistant to hepatic cholesterol accumulation upon 
challenge [163]. 
1.3.3.2 Hepatic lipogenesis 
  LXRs have also been suggested to regulate hepatic fatty acid biosynthesis. 
This process was shown to be mediated by a number of LXR target genes, 
including SREBP-1c, fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC) 
and stearoyl-CoA desaturase (SCD)-1[153, 164-165]. LXRE was identified in the 
promoter region of SREBP-1c [166]. The treatment of either LXR or RXR ligand 
could both induce the promoter activity of SREBP-1c. Deletion of LXRE on the 
promoter of SREBP-1c diminished the antagonizing effect of PUFA on SREBP-1c 
promoter activity [156].  
   The first in vivo evidence was LXRα-/- mice were found to have significantly 
reduced expression of SREBP-1c, FAS and SCD1 in the liver [163]. LXRα-/- mice 
exhibited significantly reduced hepatic fatty acid synthesis and decreased 
incorporation of palmitoleic and oleic acid into triglycerides [165].  
1.3.3.3 Glucose sensor 
  Glucose and its derivatives were also found to stimulate the activation of 
LXRs, with higher potency on LXRα than LXRβ [167]. Two LXRE were identified 
on the promoter region of Carbohydrate response element binding protein 
(ChREBP), indicating the crosstalk between carbohydrate metabolism and 
lipogenesis might be mediated by LXRs [168]. Moreover, functional LXRE was 
also identified in the promoter region of glucose transporter 4 (GLUT4), a key 
regulator for cellular glucose uptake [169]. Activation of LXR was shown to 
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induce the expression of GLUT4 and enhance insulin-stimulated glucose uptake 
into 3T3-L1 cells. However, this effect was not observed in skeletal muscle in 
rodents [170]. This may indicate the tissue specific regulation of LXR target 
genes [171].  
 
1.3.3.4 Inflammation  
In addition to LXRs’ role of regulating macrophage cholesterol efflux, a few 
studies have also suggested that LXR participate in inflammatory response. For 
example, activation of LXR was found to suppress the expression of 
inflammatory genes induced by LPS or cytokine [172]. In another study, microbial 
induced activation of TLR3 or TLR4 signaling was found to block the LXR-
mediated induction of ABCA1 [173]. These data was further supported by the 
finding that LXR-/- mice are more susceptible to infection with intracellular 
bacterial Listeria monocytogenes (LM). Interestingly, wild-type bone marrow 
transplanted into LXR-/- reduced the susceptibility of LXR-/- to LM infection [174]. 
This study has reported that scavenger receptor cystine-rick repeat protein (SPα), 
a protein that plays a crucial role in regulating macrophage survival and 
apoptosis, is also a LXR /RXR target gene.  
  In summary, the reported functions for LXRs have been far beyond their 
initial characterized role of being a cholesterol sensor. With the identification of 
LXRE on the promoters of many genes, LXRs have been found to participate in 
various tissues and physiological events, including angiogenesis [175], cell 
proliferation [176], epidermis repair [177], reproduction [178] and adrenal 
hormone secretion [179]. 
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1.3.4 Pharmacological effect of LXR agonist 
  The observation that LXRs upregulate ABCA1 and ABCG1, genes known to 
be atheroprotective, is encouraging for therapeutic targets of atherosclerosis. The 
first company to file a patent application for a series of non-steroidal LXR 
modulators is Tularik Inc. (Li L et al, WO0054759A2 and WO0054759A3, 2000). 
Their exemplified compounds include T314407 and T0901317. 
GlaxoSmithKline’s has also filed application for LXR agonists with a series of 
alkylaminoalkoxy arylalkanoate derivatives (Collins JL et al, WO0224632A2 and 
WO0224632A3, 2002). Their exemplified compound is GW3965. T0901317 and 
GW3965 are commonly used in laboratory experiment (structure shown in Fig 
1.4). Both of them have EC50 for LXRα and β in nanomolar range [180-181]. 
Although T0901317 has greater affinity to LXRs (~20 nM for both LXRα and 
LXRβ), compared to GW3965 (EC50=30 nM for LXRα and EC50=190 nM for 
LXRβ), it is not a selective LXR agonist. It can also activate pregnane X receptor 
(PXR)[182] and farnesoid X receptor (FXR)[183], but the affinity of T0901317 to 
PXR and FXR is much lower than LXR (EC50 in µM range).  
   Synthetic LXR agonists have been widely tested in various animal models for 
their effect on hypercholesterolemia and atherosclerosis. For example, 8-week 
oral administration of T0901317 to LDLr-/- mice (3 and 10 mg/kg/day) was shown 
to increase the expression of ABCA1 in aortic root and reduce atherosclerotic 
lesions without affecting total cholesterol level [184]. In another study, 6 days of 
intraperitoneal injection with a higher dose of T0901317 (50 mg/kg/day) 
significantly increased the expression of ABCA1 in duodenum (10 fold). ABCA1 
and ABCG1 were increased 2 fold in the liver [185]. Both LDLR-/- or apoE-/- mice 
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fed a diet containing GW3965 had decreased atherosclerosis [186]. ApoE-/- mice 
fed with GW3965 (10 mg/kg/day) showed strong induction of ABCA1 expression 
in the intestine and aorta [186]. C57BL/6 mice intraperitoneally injected with 
GW3965 (10 mg/kg/day and 50 mg/kg/day) had significantly upregulated 
expression of ABCA1 in the liver and duodenum after 6 days [185].  
    As previously mentioned, in vitro studies have reported a number of 
lipogenic genes modulated by LXR, which was also proven in animal 
experiments. In male C57BL/6 mice fed a diet of 6.2% fat and 0.01% cholesterol, 
were gavaged daily for 4 days 10mg/kg T0901317 or vehicle. The T0901317 
treated group was found to have significantly increased (2-5 fold) hepatic 
expression of SREBP-1c, ACC and FAS [187]. ApoE-/- mice fed GW3965 (10 
mg/kg/day) for 12 weeks showed significant upregulation of SREBP-1c in the 
liver and small intestine [186]. C57BL/6 mice fed with GW3965 (50 mg/kg/day) 
for 6 days showed increased expression of SREBP-1c, ACC and FAS in the liver 
[185]. 
  The published animal studies have suggested that the therapeutic effect of 
LXR agonists for atherosclerosis may be compromised by their side effect of 
enhancing hepatic lipogenesis, by inducing the lipogenic gene expression. It 
would be more viable if LXR agonists can act on a tissue specific manner. Based 
on the different tissue distribution of LXRα and LXRβ, it has been proposed that a 
selective agonist for LXRβ may be effective in treating atherosclerosis, without 
negative side effect on lipogenesis[188] [189]. However, due to high structural 
similarity, the development of different agonists for LXRα and LXRβ may be 
challenging. One LXRβ specific agonist has been reported, however, this agonist 
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was shown to be inactive in vivo [190].  
 
1.3.5 LXR and adipogenesis 
  As summarized in 1.3.3.2, most studies investigating LXR regulation of 
lipogenic genes have focused on the liver. Additional evidence has indicated the 
potential role of LXRs in adipogenesis / lipogenesis in adipose tissue. The 
expression of LXRα is induced during adipocyte differentiation, while LXRβ is 
constitutively expressed during adipogenesis [191-192]. A number of studies 
have shown that activation of LXR can lead to enhanced adipocyte lipid droplet 
accumulation and adipocyte-specific gene expression in vivo and in vitro [192-
194]. Two key adipogenic regulators, PPARγ [193] and aP2 [195] are both novel 
LXR target genes, with LXREs containing in their promoters. The expression of 
PPARγ and aP2 is highly induced by LXR agonist treatment. Conversely, LXRα 
expression is also increased by treatment with PPARγ ligand [196], suggesting 
crosstalk between these two transcription factors. Interestingly, different isoforms 
of C/EBPs have differential modulation on LXRα promoter activity [197]. In 3T3-
L1 preadipocytes, C/EBPα increased LXRα promoter activity, whereas C/EBPβ 
and γ did not have any effect. This study has suggested that the role of LXR in 
adipogenesis may be downstream of C/EBP activation. However, in a few studies, 
LXR activation did not show any effect in adipocyte differentiation, but played an 
important role in adipocyte gene expression and adipocyte function [191, 196]. 
For example, treatment of T0901317 did not affect adipogenesis, but increased 
basal glucose uptake, glycogen synthesis, glycerol and free fatty acid efflux, as 
well as cholesterol synthesis in differentiated 3T3-L1 adipocytes [191]. Treatment 
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with another LXRα agonist, GW3965, did not show any effect on lipid 
accumulation or the expression of PPARγ in 3T3-L1 or 3T3-F442A; however, it 
elevated the expression of GLUT4 and apoD in differentiated 3T3-L1 cells [196, 
198].  
       The role of LXR in adipogenesis was supported by LXR-/- mice. LXR-/- mice 
fed a normal rodent diet had reduced body weight and adiposity, and a defect in 
their ability to properly synthesize fatty acids and triglyceride or store them in liver 
and adipose tissue [192, 199-200]. Interestingly, the functions of LXRα and LXRβ 
in adipose tissues are not redundant. LXRβ-/- mice have significantly reduced 
body weight and adiposity, compared to their control mice, while LXRα-/- mice do 
not exhibit a lean phenotype [200]. This study has also suggested the possibility 
that LXRs are not required for adipocyte differentiation in mice, since the number 
of adipocyte may not be changed. However, LXRβ may be required for the 
expansion of adipocyte cell size and the accumulation of TG. 
  The role of LXRs in adipogenesis was suggested by a lot of evidence; 
however, the mechanism by which LXR enhances adipogenesis has not been 
consistent. One study concluded that LXR activation led to induction of both 
adipogenesis and lipogenesis during adipocyte differentiation, and this induction 
is dependent on PPARγ [193]. However, another study reported that LXR agonist 
T0901317 stimulated preferentially TG accumulation in human preadipocytes via 
the induction of de novo lipogenesis, rather than activating the differentiation 
process through PPARγ activation [194]. Despite the inconsistencies in the 
literatures about the mechanism, it is agreed that activation of LXR increases TG 
accumulation in adipocytes. 
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1.4 Experimental Overview 
Our laboratory has made the novel observation that the deficiency of GX 
sPLA2 (GX-/-) led to increased body weight and adiposity in C57BL/6 mice, even 
when fed a normal diet. Interestingly, the obese phenotype in GX-/- is not 
accompanied with increased food intake and energy expenditure. The increased 
adipocyte hypertrophy is even more pronounced when the mice were challenged 
with high fat diet feeding. In my study, I am going to use various in vitro model 
systems to manipulate the activity / expression of GX sPLA2 to investigate the 
mechanism by which GX sPLA2 regulates adipogenesis, TG storage and 
mobilization (Fig 1.5).  
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Figure 1.1 Hydrolytic reaction by secretory phospholipase A2 
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Figure 1.2 Structures of several commonly used sPLA2 inhibitors 
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Figure 1.3 Tissue distribution of GX sPLA2 in mice 
 
 
 
Tissues were collected from C57BL/6 mice and RNA was extracted. Real time 
PCR was performed to analyze the expression of GX sPLA2. 
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Figure 1.4 Two synthetic LXR agonists 
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Figure 1.5 Model for GX sPLA2 in adipogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Xia Li 2010 
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CHAPTER 2 
METHODS 
Mice 
Male C57BL/6 mice were purchased from the Jackson Laboratory. GX 
sPLA2 deficient (GX-/-) mice were generated by InGenious Targeting Laboratory, 
Inc. (Stone Brook, NY) using embryonic stem cells derived from C57BL/6 mice. 
Unless otherwise indicated, age-matched male GX+/+ and GX-/- mice produced 
from heterozygous breeding were used for all experiments. Mice were fed normal 
rodent diet ad libitum and housed in rooms with 14 h light and 10 h dark. For 
body weight and food consumption measurements, GX+/+ and GX-/- mice were 
singly caged at weaning. Daily food intake was monitored for 8 consecutive 
weeks beginning at 3 weeks of age. The fat and lean mass of 1-year-old mice 
was determined by dual energy X-ray absorptiometry (DEXA) (GE Lunar 
PIXImus, Madison, WI) as previously described [201]. For O2 consumption and 
respiratory exchange ratio (RER), mice were individually caged in the LabMaster 
Metabolism Research Platform (TSE, Chesterfield, MO). O2 consumption and 
CO2 production were measured every 30 min for a total of 72 h. Animal 
procedures were performed with the approval of the Lexington Veterans Affairs 
Medical Center Institutional Animal Care and Use Committees. 
Immunohistochemistry of mouse F4/80 for adipose tissue 
Adipose tissue was collected from GX+/+ and GX-/- mice. Tissues were 
fixed in 10% formaldehyde, paraffin embedded and cut into 5-µm sections. In 
order to deparaffinize and hydrate the tissues, sections were processed through 
34 
 
several procedures using the following solutions: Xylene 10minutes*2, 100% 
ethanol 10minutes *2, 90% ethanol 10 minutes *2, 70% ethanol 10 minutes *2 
and PBS 10 minutes *2.  To remove the protein cross-linking after paraffin 
embedding, tissues were steam-heated for 25 min in 1x Target Retrieval Solution, 
Citrate pH = 6.0 (stock is 10x) (DAKO, Carpinteria, CA) (~95 °C).  To prevent the 
specimen from falling off from the glass slides, after heating, the Retrieval 
Solution was gradually cooled down to room temperature before the slides were 
removed from the buffer (around 1h).  Slides were fixed using ice-cold ethanol for 
15 min, and then quenched using 3% H2O2 in methanol for 20 minutes (prepared 
immediately prior to use). Samples were blocked with normal rabbit serum 
(50µL/1ml PBS) (Vector Laboratories, Burlingame, CA) and then incubated the 
samples in primary rat α mouse F4/80 (AbD Serotec, Raleigh, NC) (1:100) at 
4 °C overnight, followed by biotinylated anti-rat IgG for 1 h and ABC reagents 
(Vector) for 30 min, according to the manufacturer’s protocol. Sections were then 
counter stained with hematoxylin (Vector Laboratories) for 30 sec.   
Adipocyte area measurement and adipose tissue macrophage (ATM) 
quantification 
Adipocyte area was quantified for 3 randomly selected sections from 2 or 
3 mice per group using Image-Pro computer software (Media Cybernetics). For 
quantification of ATM, 3-5 image areas were randomly chosen from each mouse 
of 3 mice per group. The number of ATM was manually counted for each slide, 
and normalized as percentage of total cell number.  
Primary stromal vascular fraction (SVF) isolation 
The SVF was isolated from adipose tissues of male GX+/+ and GX-/- mice 
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as previously described [202-203]. Briefly, tissue (1 g tissue / 5mL solution) was 
incubated in 37°C for 1 h in Krebs buffer containing 1 mg/mL collagenase type I 
(Worthington, Lakewood, NJ) and 1% fatty acid free bovine serum albumin (BSA). 
The digested tissue was spun at 500g and the SVF pellet was collected (Fig 2.1).  
SVF culture and differentiation 
SVF cells were differentiated into adipocytes ex vivo by a modification of a 
published protocol [203].  Cells were plated (50,000 cells per cm2) and 
maintained in culture media (DMEM/F12 1:1, 10% FBS, 8 mg/L biotin, 4 mg/L 
pantothenate, 2 mM L-glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin).  
Two differentiation protocols were compared:  
1) SVF cells were incubated in culture media supplemented with 10 µg/ml 
transferrin, 0.02 µM insulin, 0.2 nM thyroid hormone T3, 25 nM 
dexamethasone, 0.5 mM IBMX and 2 µM rosiglitazone (Smith Kline 
Beecham) for 4 days. Cultures were replaced with fresh media 
containing 10 µg/ml transferrin, 0.02 µM insulin and 0.2 nM thyroid 
hormone T3 every two days, and cultured up to 10 days (protocol 
adopted from Dr. Jun Liu, University of Kentucky).  
2) SVF cells were incubated for 2 days in culture media supplemented 
with 0.1 µM insulin, 1 µM dexamethasone, and 0.5 mM IBMX. Cells 
were subsequently incubated for an additional 2 days in culture media 
containing 0.1µM insulin, and then maintained in culture media without 
supplementation for another 3 days.  
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3T3-L1 cell culture and differentiation 
3T3-L1 cells were obtained from the American Type Culture Collection and 
maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 U/mL 
penicillin and 50 µg/mL streptomycin. To keep its ability to differentiate, 3T3-L1 
fibroblasts were continuously maintained at a low density (30-50% confluence) as 
well as lower number of passage (up to 10 passages). Cells were plated in 12-
well plates at ~5000 cells/ cm2. To induce differentiation, at 2 days post 
confluence, 3T3-L1 cells were incubated in culture medium supplemented with 
(0.1 µM, Sigma, St. Louis, MO), dexamethasone (1 µM; Sigma), and 3-Isobutyl-
1-methylxanthine (IBMX) (0.5 mM; Sigma). After two days, cells were incubated 
in fresh culture medium supplemented with only 0.1 µM insulin for additional two 
days. Cells were then maintained in culture medium for another 3 days.  
OP9 cell culture and differentiation 
OP9 cells were generously provided by Dr. Jianhua Shao (University of 
California, San Diego). OP9 preadipocytes were maintained and differentiated 
into adipocytes as previously described [204]. Briefly, cells were grown in MEMα 
(Invitrogen, Grand Island, NY) supplemented with 20% FBS, 2 mM L-glutamine, 
50 U/mL penicillin and 50 µg/mL streptomycin. For differentiation, OP9 cells were 
cultured for 2 days post-confluence, and then incubated for 2 days in MEMα 
supplemented with 15% KnockOutTM SR (Invitrogen, Carlsbad, CA), 50U/mL 
penicillin and 50 µg/mL streptomycin. Medium was switched back to culture 
medium and incubated an additional of two days. When indicated, OP9 
preadipocytes were incubated with differentiation medium supplemented with 5 
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µm T0901317 (Cayman, Ann Arbor, MI), a specific agonist for LXR [181].  
Adipocyte differentiation in the presence of Indoxam 
Me-indoxam (stock 1mg/mL, generously provided by Dr. Michael Gelb, 
University of Washington at Seattle) was diluted as 1:1000 into the medium. One 
day before differentiation, OP9 preadipocytes were cultured in medium 
supplemented with Me-indoxam or vehicle control (DMSO) for overnight. To 
differentiate the cells, cells were treated with differentiation medium 
supplemented with Me-indoxam or DMSO. After two days, media was replaced 
with culture medium supplemented with Me-indoxam or DMSO and grown for 
another two days. 
Generation of stably transfected OP9 cell lines 
All of the results from studies of stably transfected OP9 cells were 
confirmed using two independently transfected and selected cell lines. C-terminal 
Flag-tagged GX sPLA2 cDNA (GX-Flag) was constructed using forward and 
reverse oligonucleotides containing Hind III and EcoRI restriction sites, (F), 5’- 
CTG AAG CTT ATG CTG CTG CTA CTG -3’) and (R) 5’- GCT GAA TTC TCA 
CTT GTC ATC GTC GTC GTC GTC CTT GTA GTC GTC GCA CTT GGG TGA -
3’. The PCR product was inserted into the mammalian expression vector pcDNA 
3.1 (Invitrogen, Carlsbad, CA). An expression plasmid encoding Flag-tagged 
inactive GX sPLA2 (H46Q-Flag) [205] was generated using the QuickChange kit 
(Stratagene, La Jolla, CA) and the primers (F) 5’- CTG GTG CTG CTA CCA CCA 
AGA CTG CTG CTA CTC C -3’ and (R) 5’- GGA GTA GCA GCA GTC TTG GTG 
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GTA GCA GCA CCA G -3’. All expression plasmids were confirmed by DNA 
sequencing. OP9 and 3T3-L1 preadipocytes were plated in 6-well plates at the 
density of 7000 cells/cm2. At ~70% confluence, cells were transfected with 4 µg 
of expression plasmids using the OptifectTM reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s protocol. Transfected cells were maintained in 
culture medium containing 500 µg/mL G418 (Invitrogen) to select for control cells 
(OP9-C, 3T3-C cells) and cells expressing active (OP9-GX, 3T3-GX cells) or 
inactive (OP9-H46Q cells) GX sPLA2.  Phospholipase A2 activity in 48 h-
conditioned media from the transfected cells was determined using the sPLA2 
Assay Kit (Cayman, Ann Arbor, MI) and normalized to cellular protein.   
Cellular TG measurements 
Total lipid was extracted from cells using hexane:isopropanol (v:v =3:2), 
dried under a stream of nitrogen gas, and solubilized in chloroform containing 1% 
Triton-X100. Samples were dried again and resuspended in water. TG was 
quantified using InfinityTM Triglyceride kit (Thermo Scientific, Middletown, VA) and 
normalized to cellular protein, which was determined using BCA protein assay 
reagent (Pierce, Rockford, IL). 
Oil red O staining 
Cells were washed twice with phosphate buffered saline (PBS) and fixed 
in 10% formaldehyde for15 min, rinsed with 60% isopropyl alcohol, and stained 
with 0.3% Oil Red O in 60% isopropanol for 30 min. Cells were counter-stained in 
hematoxylin for 30 sec and mounted in 30% glycerol. 
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RNA isolation and real time PCR 
Total RNA was isolated from cells and tissues using TriZol reagent 
(Molecular Research Center, Cincinnati, OH) as recommended by the 
manufacturer. The reverse transcriptase reaction was carried out using 0.2 µg of 
RNA and a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA). Real time PCR was performed using Power SYBR Green PCR 
Master Mix (Applied Biosystems, Warrington, UK) and the following parameters: 
30 sec at 94ºC, 30 sec at 55 ºC, and 30 sec at 72 ºC for 40 cycles, and a final 
extension step at 72 ºC for 10 min. The sequences of primers used for RT-PCR 
are presented in Table 2.1.  
TG turnover rate measurement 
The rate of TG turnover was measured by a modification of a previously 
described procedure [206]. Briefly, confluent monolayers of OP9-C, OP9-H46Q, 
and OP9-GX preadipocytes were cultured overnight in delipidated medium 
(DMEM/Low glucose, 10% delipidated serum [SeraCare, Milford, MA], penicillin 
and streptomycin), and then incubated in the same medium supplemented with 
0.37 µCi / mL 3H-oleic acid (PerkinElmer, Boston, MA) for 16 h. The labeling 
medium was then replaced with fresh delipidated medium containing 6 µM 
triacsin C (Biomol Research Laboratories, Plymouth Meeting, PA) to block re-
esterification of fatty acids. Cells were collected at selected intervals up to 32 h in 
homogenization buffer (250 mM sucrose, 1 mM EDTA, 20 mM Tris-HCl, pH 7.4). 
Lipid was extracted in chloroform: methanol (2:1, v:v) with 0.6 mg/ml triolein 
added as a carrier. Samples were applied to POLYGRAM silicon membranes 
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(Macherey-Nagel, Easton, PA) and separated by thin layer chromatography (TLC) 
in hexane/ethyl ether/acetic acid (80:20:1, v/v/v). Lipid bands were visualized by 
exposing the TLC plates to I2 vapor. The amount of 3H-oleate remaining in the TG 
pool was measured in a γ counter (Cobra II, Packard Instrument Co., Minneapolis, 
MN), and normalized to cellular protein.  
TG synthesis measurement 
The rate of incorporation of 3H-oleate into TG was measured in OP9 cells 
treated with diethyl-p-nitrophenyl phosphate (E600) (Sigma), which had been 
shown previously to block lipolysis in 3T3-L1 preadipocytes [206]. To confirm the 
effectiveness of E600 in OP9 cells, I performed control experiments to measure 
TG turnover as described above, except that in addition to triacsin C, 0.6 mM 
E600 was present during a 24 h chase period. For measuring TG synthesis, 
confluent OP9-C, OP9-H46Q, and OP9-GX cells were incubated for 4 h with 
delipidated medium containing 0.37 µCi/ mL 3H-oleate, 400 µM oleate complexed 
to BSA, and 0.6 mM E600. The amount of 3H-oleate incorporated in TG was 
determined by TLC as described above. For measurements of oleate 
incorporation into diacylglycerol (DAG), 0.6 mg/ml DAG was added as a carrier 
and the lipid extracts were analyzed in the same TLC solvent system as for TG. 
For phosphatidylcholine (PC) measurements, PC was added as carrier, and the 
lipid extracts were separated in chloroform/methanol/water (65:25:4, v/v/v). 
Lipolysis measurement 
Basal medium: DMEM (low glucose) supplemented with 2% fatty acid free 
BSA, 50 U/mL penicillin and 50 µg/mL streptomycin. For isoproterenol-stimulated 
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lipolysis, isoproterenol (Sigma) was solubilized in water as stock of 10 mM, and 
diluted 1:1000 in the basal medium. For forskolin treatments, forskolin (Sigma) 
was solubilized in DMSO as stock of 25 mM, and then diluted 1:5000 in the basal 
medium. Basal medium or media containing isoproterenol or forskolin were 
added into the cells, and 50 µL of medium was collected at selected intervals. 
Glycerol in the medium was measured using Free Glycerol Determination Kit 
(Sigma). FFA was measured by HR Series NEFA Color Reagent (Wako Pure 
Chemical Industries, Osaka, Japan). Glycerol and FFA were calculated according 
to the manufacturer’s protocol and normalized to cellular protein.  
TG hyrolase activity assay 
Differentiated adipocytes were washed with PBS and collected in cell 
lysate buffer (0.25 M sucrose, 1mM EDTA, 1mM DTT, protease inhibitor and 
phosphate inhibitor). For TG substrate, 973.6 µL potassium phosphate (0.1 M pH 
7.0), 10 µL PC, 10 µL phosphatidylinositol (PI) and 6.4 µL triolein were emulsified 
by sonication for 20 X substrate. 100 µL 20X substrate, 48 µL 3H-triolein, 852 µL 
potassium phosphate (0.1 M) were emulsified by sonication to make 2X 
substrate. In each reaction, 100 µL protein lysate, 50 µL 10% BSA, 50 µL 3H 2X 
substrate were mixed for 30 min.  To stop the reaction, 3.25 ml of Reaction-stop 
solution 1 (methanol: chloroform: heptanes, 10:9:7) and 1 ml of Reaction-stop 
solution 2 (0.1 M potassium carbonate, 0.1 M boric acid, pH 10.5) were added 
into the reaction mix. The mixture was vortexed for 10 sec and centrifuged at 
800g for 15 min. 1 ml of the upper phase was removed, and 10 mL of scintillation 
fluid was added. The radioactivity of the released 3H-labelled fatty acids was 
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determined by scintillation counting in γ counter. 
Western blots 
Differentiated adipocytes were treated with isoproterenol or forskolin for 30 
min as described above. Cells were washed twice with PBS and protein was 
extracted using RIPA buffer (Sigma) supplemented with protease inhibitor 
cocktail tablet (Roche Diagnostics, Indianapolis, IN) and 100 X HaltTM 
Phosphatase Inhibitor (Thermo Scientific, Rockford, IL). Protein concentration 
was estimated using BCA protein assay reagent. A total of 15 µg of total protein 
was separated on 4-20% gradient SDS-PAGE polyacrylamide gels (BioRad 
Laboratories, Hercules, CA). Proteins were transferred onto a PVDF transfer 
membrane (Millipore Corporation, Billerica, MA). Blots were blocked for 1 h at 
room temperature in PBS with 0.2% Tween-20 (PBST) and 5% nonfat dried milk, 
followed by an overnight incubation at 4 °C in the presence of primary antibodies.  
After washing the blots three times for 5 min each with PBST, membranes were 
incubated for 1 h at room temperature with HRP-linked secondary antibodies, 
and bands were visualized using AmershamTM ECLTM Western Blotting Detection 
Reagents (GE HealthCare, Buckinghamshire, UK).  
Confocal Immunofluorescence 
Fully differentiated adipocytes were trypsonized and replated at 30%-50% 
of their original density on coverglasses in 12-well plates. Cells were grown for 
another two days. Before staining, cells were fixed with 10% formaldehyde for 15 
min. Specimens  were blocked in microscopy buffer (1% BSA, 0.1% saponin in 
PBS) containing 50µL/mL goat serum (Vector Laboratories, Burlingame, CA) for 
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1 h. Coverglasses were incubated with primary antibody in microscopy buffer for 
1 h (1:400 dilution), and washed three times with PBS. Coverglasses were then 
incubated with Alexa-conjugated secondary antibody (1:400 dilution) in 
microscopy buffer for 1 h, and then washed with PBS for three times. For lipid 
droplet staining, BODIPY (Invitrogen) was diluted into the microscope buffer (0.3 
µg/mL) along with secondary antibody. Slides were mounted in mounting medium 
for fluorescence with DAPI (Vector Laboratories).   
LXRE reporter assays  
LXRE reporter and mLXRα plasmids were generously provided by Dr. 
Peter Tontonoz (University of California, Los Angeles). OP9-C, OP9-GX, 3T3-C, 
and 3T3-GX cells were transfected with an Amaxa® Cell Line Nucleofector Kit 
V(Lonza, Germany)  following the manufacturer’s protocol using 0.5 µg pTK-
3xLXRE-Luc reporter construct, 0.5 µg mLXRα and 0.01 µg renilla luciferase per 
1 x 106 cells. Additional reporter assays were performed in OP9 and 3T3-L1 
preadipocytes transiently expressing GX sPLA2, in which case cells were 
transfected with 0.5 µg GX-Flag or control expression plasmid along with pTK-
3xLXRE-Luc, mLXRα, and renilla luciferase as described above.  24 h after 
transfection, fresh medium containing 5µM T0901317 or an equal volume of 
vehicle (DMSO) was added to the cells and incubated for 8 h. Luciferase 
activities were analyzed using the Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI). Transfection efficiency was normalized using renilla 
luciferase activity.  
Statistical Analyses 
           Mean and standard error of the mean (SE) were calculated for each 
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parameter.  Statistical significance in experiments comparing only 2 groups was 
determined by a 2-tailed Student’s t test. Unless otherwise indicated, the 
significance of the difference in mean values among more than 2 groups was 
evaluated by 2-way ANOVA using a Tukey post hoc test (SigmaStat). For 
assessment of weight gain, data was analyzed by 2-way ANOVA with repeated 
measures.  Statistical comparison between 2 genotypes within the same 
treatment group and between different treatment groups within the same 
genotype was carried out for each experiment, and all significant differences 
(P<0.05) are given in the figures and/or figure legends.    
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Table 2.1: Primer sequence for real time RT-PCR  
Genes Forward Reverse 
36B4 5'-AAG CGC GTC CTG GCA 
TTG TCT-3' 
5'-CCG CAG GGG CAG CAG 
TGG T-3' 
18s 5'-CGG CTA CCA CAT CCA AGG 
AA-3' 
5'-GCT GGA ATT ACC GCG 
GCT-3' 
PPARγ 5’- GAT GGA AGA CCA CTC 
GCA TT-3’ 
5’- AAC CAT TGG GTC AGC 
TCT TG-3’ 
aP2 5’-TCA CCT GGA AGA CAG 
CTC CT-3’ 
5’-AAG CCC ACT CCC ACT 
TCT TT-3’ 
SREBP-1c 5'-GGA GCC ATG GAT TGC ACA 
TT-3’ 
5'-GGC CCG GGA AGT CAC 
TGT-3' 
FAS 5'-GGA GGT GGT GAT AGC 
CGG TAT-3' 
5’-TGG GTA ATC CAT AGA 
GCC GAG-3'  
SCD1 5’-TCT CAG AAA CAC ACG 
CCG ACC-3’ 
5’-AGG CCG GGC TTG TAG 
TAC CTC-3’ 
F4/80 5’-CTT TGG CTA TGG CCT TCC 
AGT C-3’  
5’-GCA AGG AGG ACA GAG 
TTT ATC GTG-3’  
GX sPLA2 5’-ATT CAG CGA AGC AAC 
CAG GAG-3’ 
5’-CCA CCA AGG CCA CAA 
TAA CAG-3’. 
ADPrf6 5’-GGA GCT GCA CCG CAT TAT 
CA-3’ 
5’-CTC ATG GGG TTT CAT 
GGC ATC-3’ 
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Figure 2.1 Procedure for adipose tissue fractionation 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Xia Li 2010 
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CHAPTER 3 
GX sPLA2 deficient mice have increased adiposity 
Introduction  
Obesity has become a major public epidemic. The prevalence of obesity 
has largely increased for both adults and children, especially in the western 
countries. Obese individuals, with excess expansion of adipose tissues, are 
predisposed to a number of diseases, including type II diabetes, atherosclerosis, 
non-alcoholic fatty liver and cancer [207] [208]. It has been estimated that obesity 
is responsible for >300,000 deaths each year in the United States [209]. Thus, 
insights into the molecular mechanism of obesity and adipose tissue biology are 
needed.  
Animal models have provided insights into the etiology of obesity, 
especially mouse models being a powerful tool. A widely used obese mouse 
model is the ob/ob strain, which lacks the expression of the appetite controlling 
hormone, leptin [210]. ob/ob mice are extremely hyperphagic and develop severe 
obesity on normal diet feeding at an early age. Interestingly, the hyperphagia and 
obese phenotype of ob/ob mice can be reversed by leptin supplementation [211]. 
Later, another model was developed lacking the expression of the leptin receptor, 
known as db/db mice [212]. The phenotype of db/db mice is similar to ob/ob mice, 
except that their obesity cannot be reversed by supplementation with leptin [211].  
Among the different members of the sPLA2 family, GX sPLA2 exhibits the 
most potent activity towards phospholipids on mammalian membranes. Studies 
in vitro indicate that hydrolysis by GX sPLA2 produces the most potent release of 
arachidonic acid (AA) and lysophosphatidylcholine (PC) [29, 54], which is linked 
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to prostanoid formation. Interestingly, a study using lipoprotein substrates has 
shown the preferential release of AA from PCs by GX sPLA2 [55], which could 
further explain the high capacity of GX sPLA2 to mediate AA release.  Studies 
using genetically engineered mice have implicated GX sPLA2 in several 
pathological conditions, such as airway inflammation [59] and myocardial 
infarction [62]. However, the posttranslational regulation of GX sPLA2 activity has 
presented a difficulty in studying its function. GX sPLA2 transgenic (Tg) mouse 
neonates showed minimal respiratory phenotype, with normal alveolar 
architecture and surfactant composition. In contrast, GV sPLA2 Tg mice had 
severe lung atelectasis with thickened alveolar walls and narrow air spaces [63]. 
The authors explained that the lack of phenotype in GX sPLA2 transgenic mice 
could be due to the fact that GX sPLA2 isoform mostly remains an inactive 
zymosan under physiological conditions. The regulation of proteolytic cleavage 
for GX sPLA2 activation is not known, although there has been evidence 
suggesting the increased cleavage and activity of GX sPLA2 during inflammation 
[63].   
Studies in our laboratory indicate that GX sPLA2 is widely expressed in 
various tissues in mouse, including adipose tissues (Chapter 1, Fig.); however, 
no study has suggested the role of GX sPLA2 in adipose tissue. In order to define 
the physiological function of GX sPLA2 in vivo, our laboratory has generated 
C57BL/6 mice (GX+/+) with targeted deletion of GX sPLA2 (GX-/-), as shown in Fig 
3.1. Immunohistochemistry on various tissues has confirmed the lack of GX 
sPLA2 expression in the GX-/- mice, including adrenal glands [213]. We have 
made the unexpected finding that even when fed a normal diet, GX-/- gain 
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significantly more weight and have increased adiposity, compared to their 
littermate controls GX+/+. Histological staining of sections from paraffin embedded 
adipose tissues showed that adipocytes from GX-/- mice were significantly 
enlarged, compared to the control mice. These novel findings indicate that mice 
deficient in GX sPLA2 may be a new mouse model with mild obesity.  
 
Results 
GX sPLA2-deficient mice have increased body weight and adiposity, 
compared to WT controls 
We recently developed C57BL/6 mice with targeted deletion of GX sPLA2 
(GX-/- ). Unexpectedly, GX-/- mice fed a normal rodent diet were heavier compared to 
age-matched C57BL/6 mice (Fig 3.2 A, B). The difference in body weight becomes 
more pronounced with age, however, when the mice were 3-month old, adipocytes 
of epididymal fat exhibit remarkable hypertrophy (C57BL/6 mice: 1300±26 um2; GX-/- 
mice: 2700±80 um2; p<0.001) (Fig 3.3 and Fig 3.4). The enlargement of adipocytes 
is even more obvious when the mice were challenged with high fat diet (45% calorie 
from fat) for two months (C57BL/6 mice: 3400±96 um2; GX-/- mice: 4700±108 um2; 
p<0.001), although the difference in body weight was not detected during this age. In 
order to assess whether the adipocyte hypertrophy is accompanied by increased 
macrophage infiltration, I counted the number of macrophages on randomly selected 
sections, and normalized to the total cell number. Quantification of the percentage of 
macrophage in each section indicated a higher content of macrophage infiltration in 
chow diet fed mice (Fig 3.5). In contrast, in high-fat diet fed group, where the 
adipocyte area was significantly greater in GX-/-, there was no significant difference 
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in macrophage content between GX-/- and C57BL/6 controls (Fig 3.5). However, 
gene analysis showed GX-/- mice had significantly increased expression of IL-6, and 
non-significant increase in F4/80 and TNFα compared to C57BL/6 controls, after 
high fat feeding (Fig 3.6). 
GX-/- mice have increased body weight and adiposity, compared to their 
littermate controls 
In order to rule out the possibilities that the difference between GX-/- and age-
matched C57BL/6 controls may be due to difference in breeding background, 
phenotyping studies were repeated using littermates from heterozygote breeding. 
Body weights of GX+/+ and GX-/- littermates that were singly housed at weaning were 
monitored until 10 months of age. Results from this study confirmed that deficiency 
in GX sPLA2 leads to significantly increased weight gain in mice (Fig 3.7). Based on 
results from DEXA, the difference in body weight appears to be primarily due to an 
increase in adiposity in GX-/- mice; lean mass was not significantly different between 
the two strains (Fig 3.8). Histological staining of epididymal fat sections from 6-
month-old mice showed that GX-/- mice have enlarged adipocytes compared to GX+/+ 
mice (GX+/+ mice: 3630±95 µm2; GX -/- mice: 6290±144 µm2, p<0.0001) (Fig 3.9 A, 
B). The increase in adiposity did not appear to be the result of altered food 
consumption (Fig 3.10). No difference in oxygen consumption or RER was detected 
in GX-/- mice compared to GX+/+ mice (Fig 3.11), indicating that differences in 
adiposity may not be due to alterations in energy balance. 
Adipocyte hypertrophy is more pronounced in high-fat fed GX-/- mice  
In order to assess the affect of high fat feeding, GX-/- and their littermate 
controls GX+/+ were fed a high fat diet (60% calorie from fat) for 5 months, starting 
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from 1-month of age. Consistent with the previous experiment of 3-month old GX-/- 
and C57BL/6, the adipocytes in epididymal fat of GX-/- were significantly enlarged, 
compared to GX+/+ controls (Fig 3.12) (GX+/+, 5902 ± 250.3 µm2; GX-/-, 8924 ± 299.1 
µm2, ***P<0.0001). In mesenteric fat, the adipocyte size was not significantly 
different between GX+/+ and GX-/- with 10% diet feeding (GX+/+, 2776 ± 131.9; GX-/-, 
2962 ± 137.7, not significant). With 60% high fat diet feeding, the adipocytes in 
mesenteric fat of GX-/- was significantly enlarged, compared to GX+/+ (GX+/+, 4899 ± 
218.3; GX-/-, 6117 ± 213.8; ***P<0.0001) (Fig 3.13).   
SVF cells from GX-/- mice accumulate more triglyceride when differentiated 
into adipocytes ex vivo compared to GX+/+ mice 
To our knowledge, the expression of GX sPLA2 in adipose tissue has not 
been reported. In order to analyze which cell types in the adipose tissue express GX 
sPLA2, adipose tissue from 1-year-old male C57BL/6 mice was separated into SVF 
and adipocytes to analyze the expression and distribution of GX sPLA2 mRNA. 
RNAs isolated from the SVF and adipocytes were enriched more than 100-fold in 
F4/80 and aP2, respectively, confirming the effectiveness of our separation 
procedure (Fig 3.14 A, B). GX sPLA2 mRNA was detected in both adipocytes and 
SVF (Fig 3.14C). When treated with adipogenic stimuli ex vivo, SVF cells were 
efficiently differentiated into mature adipocytes, as evidenced by the presence of 
abundant intracellular lipid droplets (Fig 3.15). GX sPLA2 mRNA could be detected at 
comparable levels throughout all stages of SVF differentiation into adipocytes (Fig 
3.16). Notably, SVF from GX-/- mice accumulated significantly more TG during 
differentiation compared to GX+/+ mice (Fig 3.17).  Taken together, our data suggest 
that the increased adiposity of GX-/- mice may be due at least in part to a direct effect 
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in adipose tissue, rather than a systemic consequence of GX sPLA2 deficiency.  
 
Discussion 
The role of GX sPLA2 in mouse adipose tissue has never been reported. 
In this Chapter, we have summarized the unexpected obese phenotype of GX 
sPLA2 deficient mice. GX-/- mice have significantly increased body weight gain 
and increased adiposity, even when fed a normal diet. Although we did not 
comprehensively study the gender specificity of this phenotype, results from body 
weight measurement and DEXA analyses indicated a similar propensity for 
increased body weight and adiposity in female GX-/- mice. Unlike some genetic 
obese mouse models, such as ob/ob and db/db, the increased body weight in 
GX-/- is not attributed to increased food consumption. As we monitored the 
weekly body weight gain, we noticed that the higher body weight in GX-/- is more 
pronounced during aging. However, at a younger age (3 months or 6 months old), 
the phenotype of adipocyte hypertrophy started to appear even before the 
difference in body weight becomes significant. After high fat feeding, the 
adipocyte hypertrophy in GX-/- mice was even more pronounced.  
 At least in one study, preliminary data for epididymal fat indicated an 
increase in macrophage infiltration into the adipose tissue in GX-/- mice, 
compared to their C57BL/6 control. As previously reported, this increased 
macrophage infiltration may be the metabolic consequence of increased 
adipocyte hypertrophy, indicating higher level of inflammation in the adipose 
tissue [214]. Notably, after high fat feeding, the increased adipocyte hypertrophy 
in GX-/- mice was not accompanied by increased macrophage infiltration. 
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However, gene analysis for epididymal fat showed high fat fed GX-/- mice had 
significantly increased expression of IL-6 and non-significantly higher expression 
of F4/80 and TNFα compared to C57BL/6 mice. Interestingly, preliminary study in 
our laboratory has shown that the GX-/- mice were protected from diet-induced 
insulin resistance (data not shown). Several studies have indicated that in 
obesity, the failure to appropriately respond to the need to store excess energy in 
the form of TG may lead to metabolic disorders [74] [75]. In humans, total body 
fat mass is determined by both adipocyte number and adipocyte size, although 
the total number of adipocytes increases only in childhood and adolescence [73]. 
Nevertheless, the adipocyte population appears to undergo a remarkable rate of 
turnover in adults, yet keeping adipocyte number fixed at all levels of body mass 
index.  According to one estimate, approximately 10% of fat cells are renewed 
every year in adults, regardless of the size of the fat depot [73]. Thus, in order to 
maintain a constant number of adipocytes, feedback mechanisms must be in 
place to regulate adipogenesis and adipocyte hypertrophy when energy balance 
is perturbed. In the case of GX-/- mice, by storing excess energy in adipose 
tissue, the increased adiposity may be a protective mechanism for them to 
ameliorate diet-induced insulin resistance and systemic inflammation.  
Interestingly, studies in our group have demonstrated GX-/- mice have 
~80% higher plasma corticosterone concentrations compared to GX+/+ mice 
under both basal and ACTH-induced stress conditions [213]. Given that 
glucocorticoids exert pleiotrophic effects on whole body metabolism and energy 
partitioning, we cannot rule out the possibility that alterations in adrenal function 
may contribute to the increased adiposity in GX-/- mice. However, we found no 
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evidence that GX-/- mice had altered food intake or energy expenditure, as would 
be expected if increased corticosterone levels were having a central effect on 
adiposity [215]. Moreover, SVF isolated from GX-/- mice accumulated significantly 
more TG after being differentiated ex vivo, compared to GX+/+ SVF, which 
indicates the phenotype of adipocyte hypertrophy is generated from a primary 
change in adipocytes. 
Separation of WAT into adipocytes and SVF showed that GX sPLA2 is 
expressed in both fractions in GX+/+ mice, although transcripts were relatively 
more abundant in the SVF. The SVF comprises a population of cells that are 
capable of differentiating into several lineages [203]. We did not determine 
whether GX sPLA2 was expressed by other cell types present in the SVF (for 
example, fibroblasts, endothelial cells, and macrophages). GX sPLA2 mRNA 
expression remained relatively constant when SVF-derived cells were cultured in 
the presence of adipogenic stimuli, indicating that GX sPLA2 is not 
transcriptionally regulated during adipocyte differentiation.  
Taken together, our study has shown that GX-/- mice is a mouse model 
with mild obesity and increased adiposity. The adipocyte hypertrophy is not likely 
due to a systemic effect in the GX-/- mice, but rather a primary effect of GX 
sPLA2 in the adipocytes. In the following chapters, I am going to present several 
approaches I have used to define the role of GX sPLA2 in adipocytes.  
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Figure 3.1 Generation of mice deficient in GX sPLA2 
 
 
 
White boxes represent exons. Restriction enzyme sites are indicated. In this 
strategy, the Neo cassette is trapped inside exon 1 before the ATG and replaces 
564bps of the gene. 
WT 
B: BamHI 
E : EcoRI 
H: HindIII 
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1 KB 
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Figure 3.2 GX-/- fed a normal diet have increased body weight 
A 
 
B 
 
A) Male C57BL/6 and GX-/- mice were fed a normal rodent diet for 12 months.  
B) Male and female mice fed a normal rodent diet were weighed on 17-month of 
age. 
  
57 
 
Figure 3.3 GX-/- mice have enlarged adipocyte area, compared to C57BL/6 mice 
 
3 months old male GX-/- and C57BL/6 control mice were fed a normal diet or 45% 
high fat diet for two months. Sections of paraffin embedded epididymal fat were 
stained with anti-F4/80 antibody, and counter stained with hematoxylin. 
Magnification: 100 X.  
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Figure 3.4 GX-/- mice have enlarged adipocytes, compared to C57BL/6 mice 
 
 
One randomly selected area was sectioned from 3 mice in each group. ~35 cells 
were randomly circled and measured on each image. Mean adipocyte area (±SE) 
was determined for 3 randomly chosen area of each section. a, b, c, d, P<0.001.
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Figure 3.5 Chow diet fed GX-/- mice have increased macrophage infiltration into 
adipose tissue, compared to C57BL/6 mice 
 
3-5 image areas were randomly chosen from each mouse of 3 mice per group. 
The number of macrophage was counted and normalized to total cells number, 
as percentage of total cells.  
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Figure 3.6 GX-/- have increased expression of inflammatory genes. 
 
 
RNA was extracted from adipose tissues of 3-month-old mice (high fat diet 
feeding for 2 months), followed by real time RT-PCR to analyze the gene 
expression.  
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Figure 3.7 GX-/- have significantly increased body weight gain, compared to 
littermate controls GX+/+ 
 
Male GX+/+ and GX-/- mice were singly housed at weaning, and body weights 
were determined weekly (n=3). *P<0.05. 
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Figure 3.8 GX-/- male mice have increased adiposity 
 
 
Body composition of 12-month old male mice was determined by DEXA (n=3). 
*P<0.05. 
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Figure 3.9 The adipocytes in epididymal fat of GX-/- mice are enlarged, compared 
to GX+/+ mice 
 
 
 
A) Histological staining of paraffin-embedded epididymal fat sections from 6-
month-old mice, fed a normal diet. Magnification: 100X 
B) Mean adipocyte area (±SE) was determined for 3 randomly chosen sections, 
2 mice per strain. ***P<0.0001. 
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Figure 3.10 The food intake is similar between GX+/+ and GX-/- mice 
 
 
Daily food consumption by male GX+/+ and GX-/- singly housed mice was 
measured for 8 weeks starting at 3 weeks of age (n=4). 
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Figure 3.11 The metabolic parameters are similar in GX+/+ and GX-/- mice 
 
 
8-month old male GX+/+ and GX-/- mice were singly caged in a LabMaster 
Metabolism Research Platform. O2 consumption and CO2 production were 
measured every 30 min for a total of 72 h.  The data shown are the mean values 
(±SE) for the final two light and dark periods. 
 
66 
 
Figure 3.12 The adipocytes in epididymal fat from high fat fed GX-/- were more 
hypertrophic, compared to GX+/+ 
 
 
 
6-month old male mice were fed high fat (60% calorie from fat) diet for 5 months. 
Sections from paraffin-embedded epididymal fat were stained with anti-F4/80 
antibody and counter stained with hematoxylin.  
Magnification: 100X 
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Figure 3.13 The adipocytes in mesenteric fat of GX-/- mice were enlarged, 
compared to GX+/+ mice, after high fat feeding 
 
 
6-month old male mice were fed low fat (10% calorie from fat) or high fat (60% 
calorie from fat) diet for 5 months. Sections from paraffin-embedded mesenteric 
fat were stained with anti-F4/80 antibody and counter stained with hematoxylin. 
Magnification: 100X 
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Figure 3.14 GX sPLA2 is expressed in mouse SVF and adipocytes 
 
 
Adipocytes and SVF were isolated from collagenase-digested epididymal fat from 
1-year old C57BL/6 mice as described in Materials and Methods. F/480 (A), aP2 
(B) and GX sPLA2 mRNA in the two fractions was quantified by real time RT-PCR. 
The data presented are the mean (± SE) of triplicate samples, and are 
representative of 3 independent experiments. ***P<0.001 
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Figure 3.15 SVF from GX+/+ and GX-/- can both be effectively differentiated ex 
vivo 
 
 
SVF cells from 5-week-old GX+/+ and GX-/- mice were plated and differentiated 
into mature adipocytes as described in Materials and Methods. On the 7th day, 
cells were stained with oil red O. Representative pictures from 3 independent 
experiments are shown. 
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Figure 3.16 The expression of GX sPLA2 is not altered during SVF differentiation 
 
 
Cultured SVF cells from 5-week-old male C57BL/6 mice were treated with 
adipogenic stimuli as described in Materials and Methods. RNA was prepared 
from cells at the indicated time of differentiation for real-time RT-PCR. 
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Figure 3.17 Adipocytes differentiated from GX-/- SVF accumulate more TG, 
compared to GX+/+ SVF 
 
 
SVF cells from 5-week-old GX+/+ and GX-/- mice were plated and differentiated 
into mature adipocytes. At the indicated time of differentiation, cellular lipid was 
extracted and TG was quantified. Data are means (± SE) of triplicate samples 
and are representative of 4 independent experiments. *P<0.05.  TG content in 
both cell types was significantly higher at day 7 of differentiation compared to day 
4; ***P<0.001. 
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CHAPTER 4 
Characterization of in vitro models of adipogenesis 
Introduction 
Adipose tissue is an important energy reservoir and endocrine organ [216]. 
The excess or deficiency of adipose tissue may both lead to various metabolic 
diseases, such as insulin resistance, hyperglycemia and cardiovascular diseases 
[208, 217-218]. In addition to its role in metabolism, adipose tissue also plays a 
vital role in thermogenesis and traumatic protection [108, 219]. The major cell 
type in adipose tissue, the adipocyte, is a specific cell type that accumulates 
large amount of intracellular TG and expresses specific proteins to regulate lipid 
and glucose homeostasis.  
Most of the knowledge about adipocyte biology has been generated from 
established in vitro adipogenesis systems, including primary preadipocytes and 
engineered cell lines. A commonly used system of primary preadipocytes is the 
stromal vascular fraction (SVF) isolated from the adipose tissue after collagenase 
digestion [202-203]. The SVF is a heterogenous population of cells, including 
preadipocytes, macrophages, fibroblasts, endothelial cells and vascular cells. 
When isolated and cultured in vitro, a large portion of the cells remain the 
morphology of fibroblasts. In recent years, these cells have been defined as 
adipocyte-derived stem cells (ADSCs), since they carry some properties of 
multipotent cells [70, 220]. When treated with differentiation stimuli in vitro, these 
cells may be differentiated into various cell types including adipocytes, osteoclast 
and macrophages, depending on the treatment. Although SVF is a widely used 
model, the primary preadipocytes or adipocytes have limitations, including their 
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inconsistency due to inter-animal variability, difficulty in isolation and limited 
capacity of proliferation. Another widely used primary preadipocyte model is 
mouse embryonic fibroblasts (MEF), which is isolated from mid-gestation mouse 
embryos and cultured ex vivo. Similar to SVF, MEF can also be differentiated into 
several lineages and has limited capacity of proliferation [221].  
In the past decades, several preadipocyte cell lines have been developed 
for laboratory use, such as mouse cell lines 3T3-L1 [222], 3T3-442A [223], Ob 
1771 [224], RBM-Ad [225], human preadipocytes LS14 [226] and OP9 cells [204]. 
These cells were shown to be successfully differentiated in vitro, by treating with 
hormone-containing adipogenic cocktail. Among these systems, the most widely 
used adipocyte cell line is 3T3-L1 cells. 3T3 cells were initially generated from 
Swiss mouse embryo tissue by Todaro and Green in New York University School 
of Medicine in 1962. The nomenclature was based on its feature of “3-day 
transfer (T), inoculated at the rigid density of 3 x 105 cells”. Later, a cell line, 3T3-
L1, derived from 3T3 was found to have the capacity to undergo adipogenesis 
[222]. Under basal conditions, they remain the morphology of fibroblasts. When 
treated with medium containing adipogenic stimuli, including insulin, 
dexamethasone and 3-isobutyl-1-methylxanthine (IBMX), they accumulate large 
amounts of intracellular lipid droplets, and acquire the morphology and gene 
markers of adipocytes. This culture model of adipogenesis has been extensively 
studied in different aspects of fat cell biology, such as glucose utilization, 
adipokine secretion and crosstalk between adipocytes and macrophages. 
However, there are certain limitations with 3T3-L1. After multiple passages, or 
when propagate post confluence, the capacity of 3T3-L1 cells to undergo 
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adipogenesis may significantly diminish. Moreover, these cells require a long 
time to generate mature adipocytes (10~14 days after seeding). The transfection 
efficiency for 3T3-L1 is very low, and the demanding requirements for handling 
also limit the generation of stably transfected cells. 
In 2006, another cell line was reported to be a novel model of 
adipogenesis, namely OP9 [204]. OP9 cells were initially obtained from the skull 
cavity of newborn mice deficient in macrophage colony stimulating factor (M-
CSF). Compared to 3T3-L1 cells, OP9 cells require much shorter time to be 
differentiated into adipocytes (less than 7 days after seeding). Upon hormone mix 
treatment, they robustly accumulate abundant lipid droplets within 3-4 days. OP9 
preadipocytes maintain the capacity of adipogenesis even after a high number of 
passages (over 100). Gene expression analysis indicated that OP9 
preadipocytes are likely at a later stage of adipogenesis, compared to 3T3-L1 
cells, since a number of adipogenic genes, including PPARγ, C/EBPα and 
SREBP-1c could be detected in OP9 cells after two days post confluence, even 
without treatment of adipogenic stimuli. Interestingly, these cells were also found 
to undergo spontaneous differentiation upon reaching confluence. It was also 
shown that the adipocytes derived from OP9 cells express various adipocyte 
specific proteins, including perilipin, adiponectin and Glut4. They exhibit robust 
insulin-mediated glucose uptake, comparable to 3T3-L1 derived adipocytes.  
In order to study the role of GX sPLA2 in adipogenesis, I set out to 
establish the best in vitro model system. In my study, I investigated the three 
different in vitro model systems of adipogenesis: adipocytes derived from primary 
SVF, 3T3-L1 and OP9. In this chapter, I describe experiments I carried out to 
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optimize their conversion into adipocytes, and characterization of experiments on 
each of their cells proceed through the adipogenic program and how each of 
these cell types respond to lipolytic stimuli.  
 
Results 
OP9 and 3T3-L1 are differentiated into mature adipocytes 
Based on the protocol shown in Fig 4.1A and Chapter 2, at 100% of the 
time, OP9 preadipocytes could be successfully differentiated into adipocytes 
within 3~4 days, evidenced by oil red O staining (Fig 4.2 A). As previously 
described, OP9 cells have the capacity to undergo spontaneous differentiation 
upon reaching confluence [204]. Therefore, in untreated cells, Oil Red O staining 
showed a small portion of OP9 cells with intracellular lipid droplets (Fig 4.2 A). 
During each day of differentiation, cellular lipid was extracted and TG was 
quantified. The TG content was significantly increased during OP9 differentiation 
(Fig 4.2 B). Real time RT-PCR analysis indicated that during differentiation, OP9 
cells acquired the expression of adipocyte specific genes, PPARγ and aP2 (Fig 
4.3). As previously reported, OP9 cells expressed PPARγ upon reaching 100% 
confluence [204]. In contrast, only about 50% of the chance in my experiments, 
3T3-L1 could be successfully differentiated into adipocytes, as shown by Oil Red 
O staining (Fig 4.4). Consistent with previous report [204], 3T3-L1 adipocytes 
have large unilocular lipid droplets and peripherally displayed nucleus; whereas 
OP9 adipocytes tend to have many smaller multilocular lipid droplets (Fig 4.2 A 
and Fig 4.4).  
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Primary SVF are differentiated into adipocytes 
Unlike OP9 and 3T3-L1 cells, both of which need to reach 2 days post 
confluence, the initiation of SVF cells started around ~90% confluence (Fig 4.1 
C). Two protocols listed in Chapter 2 for SVF differentiation were tested. The first 
protocol has more hormone supplementation, including thyroid hormone T3, 
transferrin and rosiglitazone. Both of the two protocols induce effective 
differentiation of SVF from 1-month old male mice (Fig 4.5 and 4.6 A). In order to 
avoid the results being interfered by excess hormones, I chose the 2nd protocol in 
most of my studies for SVF differentiation. The capacity of SVF to be 
differentiated into adipocytes is also related to the age of the mice from which the 
SVF are isolated, with cells from younger mice having higher capacity of 
differentiation (Fig 4.6 A, B, Fig 4.7). Therefore, unless otherwise indicated, the 
results in my study were based on results from 1-month-old male mice. As shown 
by Oil Red O staining, SVF derived adipocytes also accumulate large unilocular 
lipid droplets, similar to 3T3-L1 derived adipocytes (Fig 4.5 and 4.6). RNA was 
extracted from cells on day 0, day 3, and day 7 of differentiation. The expression 
of adipogenic specific genes, PPARγ and aP2, was significantly upregulated 
during differentiation (Fig 4.8).  
Lipolysis measurement in 3T3-L1, SVF and OP9-derived adipocytes 
I next investigated the ability of 3T3-L1, SVF and OP9-derived adipocytes 
to undergo catecholamine-induced lipolysis. Isoproterenol is a known β-
adrenergic receptor agonist, which stimulates β1, β2 and β3 adrenergic receptors 
[227]. Forskolin directly elevates cAMP, which bypasses the effect of β 
adrenergic receptor [228] (compounds structure shown in Fig 4.9). As reported in 
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the literatures, 3T3-L1 cells responded robustly to both isoproterenol and 
forskolin, as evidenced by a more than 5-fold of increase in glycerol release (Fig 
4.10 B). Adipocytes derived from SVF responded similarly to 3T3-L1 adipocytes, 
with significantly elevated lipolysis when treated with isoproterenol and forskolin 
(Fig 4.10 C). In contrast, OP9 adipocytes did not respond to isoproterenol 
treatment, whereas forskolin treatment resulted in a 3-fold induction in glycerol 
release (Fig 4.10 A).  
The phosphorylation status of HSL in 3T3-L1 and OP9-derived adipocytes 
Signaling through β-adrenergic receptors leads to the activation of 
adenylyl cyclase, which resulted in an increase in cAMP-dependent protein 
kinase A (PKA) activity. PKA then phosphorylates HSL, which induces the 
translocation of HSL to lipid droplets, and subsequent TG hydrolysis. Thus, it was 
of interest to determine the phosphorylation status of HSL in OP9 and 3T3-L1 
adipocytes. Interestingly, in both 3T3-L1 and OP9 derived adipocytes, forskolin 
strongly induced the phosphorylation of Ser660 on HSL in 3T3-L1 and OP9-
derived adipocytes (Fig 4.11). However, isoproterenol induced the 
phosphorylation of Ser660 in 3T3-L1 adipocytes, but not in OP9 adipocytes (Fig 
4.11). 
The translocation of HSL in 3T3-L1 and OP9-derived adipocytes 
To directly monitor the phosphorylation status and intracellular localization 
of pHSL in 3T3-L1 and OP9 derived adipocytes, immunofluorescence staining 
was performed in untreated cells, and cells treated with isoproterenol or forskolin 
for 30 min. Consistent with the previously published findings and my lipolysis 
measurement, pHSL was barely detected by indirect immunofluorescence in 
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either 3T3-L1 or OP9 adipocytes under basal condition (Fig 4.12 and 4.13). After 
treatment with isoproterenol or forskolin, Ser660 phosphorylation was robustly 
induced in 3T3-L1 cells, which was observed as intense pHSL staining localized 
to lipid droplets (Fig 4.12). In contrast, in OP9 cells, only forskolin induced the 
phosphorylation and translocation of pHSL to the lipid droplets, which was not 
shown in isoproterenol treatment (Fig 4.13).  
The expression of ADP-ribosylation factor 6 (Arf6) in 3T3-L1 and OP9 
adipocytes 
A Ras-related GTP-binding protein, ADP-ribosylation factor 6 (Arf6) was 
found to be required for the internalization of β adrenergic receptors. In order to 
examine whether adipocytes derived from 3T3-L1 and OP9 express different 
levels of ADPrf6, RNA was collected from differentiated 3T3-L1 (day 8) and OP9 
cells (day 4). Real time RT-PCR was performed to analyze the relative 
expression of aP2 and ADPrf6. The expression of aP2 was not significantly 
different between the two cell types, indicating they were differentiated into 
comparable levels (Fig 4.14 A). There was a trend for lower expression of ADPrf6 
in 3T3-L1 adipocytes, but not significant (Fig 4.14 B).  
Discussion 
The development of adipose tissue has become the subject of interest due 
to the increasing obesity epidemic. Adipocytes derived from 3T3-L1, OP9 and 
primary SVF are all in vitro useful models for studying adipocyte biology. Among 
the three models, OP9 cells required the shortest time to be differentiated into 
adipocytes and acquire the adipocyte specific gene profiles and rapidly form 
abundant large lipid droplets. As previously reported, OP9 cells have high level of 
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PPARγ expression even without treating with differentiation stimuli, which may 
explain why they can undergo spontaneous differentiation [204]. This 
spontaneous differentiation was also seen in my experiments. Moreover, pre-
confluent OP9 preadipocytes, but not pre-confluent 3T3-L1 preadipocytes, could 
be differentiated into adipocytes by treatment of insulin and oleate [204]. 
Compared to 3T3-L1 cells, the differentiation capacity of OP9 cells are little 
influenced by passage number or cell density during propagation. With short time 
to be differentiated, OP9 cells have an advantage for plasmid transfections. Even 
for nucleofection, the efficiency for transfecting 3T3-L1 and OP9 preadipocytes 
may only be around 30% (data not shown). Low transfection efficiencies of both 
3T3-L1 and OP9 cells lead to the necessity for stable selection. During selection, 
due to high cell density in culture, the differentiation capacity of 3T3-L1cells can 
be largely impaired, but OP9 cells are barely affected.  
SVF has also been developed as a useful adipogenesis model.  A study 
using FACS analysis characterized the portion of different cell types in SVF, and 
only part of the SVF cells (CD24+) exhibited a high capacity to differentiate into 
adipocytes [203]. This study also demonstrated a model for adipocyte 
differentiation in vivo. The authors injected different cell fractions of luciferase-
labeled SVF cells into mice, and monitored their development in vivo. Consistent 
with the findings from in vitro differentiation, only CD24+ cells injected in the 
mouse epididymal fat pad successfully developed into adipose tissue. In my 
study, we chose to use younger mice, which had higher differentiation capacity. 
Two differentiation protocols described in Chapter 2 were tried, and both of them 
could effectively induce adipogenesis of SVF isolated from 1-month-old mice. In 
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order to prevent the effect of excess hormones, I used protocol 2 to differentiate 
SVF, which is the same hormone mix as 3T3-L1 differentiation. Interestingly, 
unlike OP9 and 3T3-L1 cells, both of which require contact-inhibition in order to 
reach adipocyte commitment, the initiation of SVF differentiation is around ~90% 
confluence. It is possible that the SVF cells in the adipose tissue are more 
committed to adipocyte differentiation, compared to in vitro engineered cell lines.  
There have been some published protocols for transfecting SVF, such as 
nucleofection, which has not yet been tested in my experiments. In order to 
examine the effect of GX sPLA2 in SVF adipogenesis, primary SVF cells were 
directly isolated from GX+/+ and GX-/- mice.  
With their optimized culture condition, these three systems can all be 
successfully differentiated into mature adipocytes, with OP9 having the shortest 
time of adipogenic process. However, no previously published reports have 
addressed the ability of these three cell types to respond to lipolytic stimuli. As 
described in Chapter 1, lipolysis of adipocytes TG stores is an important catabolic 
process during fasting. In mammals, dysfunctional adipose tissue lipolysis may 
be associated with compromised systemic insulin sensitivity [71-72]. The 
activation of the β-adrenergic receptor by catecholamines leads to elevated 
intracellular cAMP in adipocytes, followed by the activation of PKA. PKA can 
phosphorylate HSL, which induce the translocation of HSL to the surface of the 
lipid droplets, thereby inducing lipolysis. In human adipocytes, β1 and β2 
adrenergic receptors participate in catecholamine-induced lipolysis. In rodents, 
the β3 adrenergic receptor plays the predominant role [229]. Selected β3 
adrenergic receptor stimulation induces lipolysis and thermogenesis response in 
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rodents [230]. Numerous studies have suggested the potential therapeutic role of 
catecholamines for obesity and diabetes; however, the pharmacological effect of 
catecholamines in these settings remains to be determined.  
A number of factors known to alter adipocyte lipolysis were found to 
regulate PKA through altering cAMP, such as insulin, prostaglandin E2 (PGE2) 
[231] and glucagon [232]. Isoproterenol is a high affinity ligand for β-adrenergic 
receptors. By stimulating β1 and β2 adrenergic receptors, isoproterenol in clinic 
was shown to increase heart rate and produce vasodilatation [233-234]. The 
stimulation of β adrenergic receptors is believed to be a major mechanism for 
catecholamine-induced lipolysis in adipocytes. Forskolin is a compound 
produced by Indian Coleus plant. It was shown to activate the enzyme adenylyl 
cyclase and increase the intracellular cAMP. It is used in clinic as a vasodilator.  It 
has been commonly used in laboratory research to raise intracellular cAMP. In 
adipocyte system, it can directly activate PKA, bypassing signaling through β 
adrenergic receptor [228]. The intracellular signaling event leading to lipolysis 
can be directly shown by immunofluorescent staining. Under basal conditions, 
unphosphorylated HSL mostly remains in the cytosol. When activated, HSL is 
phosphorylated and translocates to lipid droplets. Several Serine residues are 
phosphorylated by PKA, including Ser563, Ser659 and Ser660 [235]. In my 
experiment, I used Ser660 as indicator of HSL activation.  
Although in vivo rodent models have provided invaluable insights, a lot of 
signaling analysis was based on cultured adipocytes in vitro. In my study, I have 
found that the adipocytes derived from these cell lines, SVF, 3T3-L1 and OP9 
exhibit different response to β-aderengeric receptor medicate lipolysis. I have 
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used two types of lipolysis stimuli, isoproterenol and forskolin (structure shown in 
Fig 3.9), both of which were reported to induce adipocyte lipolysis. However, the 
lipolytic mechanism for these two treatments is not identical. Isoproterenol is a 
known β-adrenergic receptor agonist, which was shown to stimulate β1, β2 and 
β3 adrenergic receptors [227]. Forskolin was shown to directly elevate cAMP, 
which bypasses the effect of β adrenergic receptor [228].  With these two 
treatments, I have compared molecular mechanism of lipolysis in these three 
adipocyte models.  
The defect of isoproterenol stimulated lipolysis in OP9 adipocytes was not 
expected, which may involve two possible mechanisms. Firstly, the expression of 
β-adrenergic receptor may be different between these two adipocyte lines. 
Secondly, the receptor trafficking on the cell membrane may be different in these 
two types of adipocyte. The receptor trafficking and internalization were found to 
regulate the efficiency of β-adrenergic receptor stimulators. For example, 
β1adrenergic receptor induced cardiac hypertrophy was shown to be blocked 
when the endocytic pathways were inhibited by Concanavalin A [236]. This effect 
was also observed in adipocytes. Arf6 was found to be required for the 
internalization of β adrenergic receptors. 3T3-L1 adipocytes with Arf6 knockdown 
resulted in significantly decreased basal and isoproterenol stimulated lipolysis 
[237]. Similarly, this effect was also observed for dynamin inhibition. Dynamin 
plays a role in vesicle formation during membrane budding, which is required for 
receptor internalization [238]. Pharmacological inhibition of dynamin also blocked 
isoproterenol induced lipolysis in 3T3-L1 adipocytes [237]. However, the lipolysis 
mediated by forskolin, which bypasses β adrenergic receptors, was not affected. 
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Insulin signaling was not affected by the lack of Arf6 either. In 3T3-L1 and OP9 
adipocytes, both of them were shown to respond robustly to insulin mediated 
glucose uptake [204]. The lipolysis response of SVF adipocytes is similar to 3T3-
L1 adipocytes, with robust response to both isoproterenol and forskolin. 
In summary, my study for the first time demonstrated the difference in β 
adrenergic receptor stimulated lipolysis between the adipocytes derived from 
3T3-L1 and OP9. Although OP9 is a model with higher efficiency for 
adipogenesis, with the advantage of easier handling and transfection, it lacks the 
ability to undergo catecholamine-induced lipolysis. The mechanism of reduced 
isoproterenol stimulated lipolysis in OP9 adipocytes remains to be elucidated. 
This requires the analysis of 1) the expression of β adrenergic receptors and 2) β 
adrenergic receptor trafficking and internalization in the two adipocyte models.  
In the studies described in the following chapters, in vitro model systems 
are used to manipulate the activity / expression of GX sPLA2 and assess their 
effects on adipogenesis and TG accumulation / mobilization. Given the 
availability of mice deficient in GX sPLA2 (GX-/-) in our laboratory, SVF isolated 
from GX+/+ and GX-/- mice provide a model for loss-of-function study. Additionally, 
in most of the studies, OP9 cells were used for different manipulation of GX 
sPLA2. Some of the results were further confirmed using 3T3-L1 cells.  
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Figure 4.1 Adipogenesis protocols for OP9, 3T3-L1 and SVF 
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Figure 4.2 OP9 cell were effectively differentiated into mature adipocytes 
 
A) OP9 cells were stained with Oil Red O before and after differentiation. 
B) During each day of differentiation, cellular lipid was extracted. TG was 
quantified and normalized to cellular protein. **P<0.01, ***P<0.001.  
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Figure 4.3 Gene expression in OP9 cells 
 
 
During each day of OP9 differentiation, cells were collected for RNA extraction, 
followed by real time RT-PCR for expression of adipogenic genes, PPARγ and 
aP2 . ***P<0.001. 
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Figure 4.4 3T3-L1 cells were differentiated into adipocytes 
 
 
 
Differentiated 3T3-L1 was stained with Oil Red O after differentiation at day 7.  
Magnification: 100X 
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Figure 4.5 Protocol 1 for SVF differentiation 
 
 
 
SVF cells were isolated from 1-month-old male C57BL/6 mice, and differentiated 
following the Protocol 1 described in Chapter 2. When 90% confluent, cells were 
treated with culture media supplemented with 10 µg/ml transferrin, 0.02 µM 
insulin, 0.2 nM thyroid hormone T3, 25 nM dexamethasone, 0.5 mM IBMX and 2 
µM rosiglitazone for 4 days. Replace fresh culture media containing 10 µg/ml 
transferrin, 0.02 µM insulin and 0.2 nM thyroid hormone T3 every two days, and 
culture for up to 10 days (protocol adopted from Dr. Jun Liu, University of 
Kentucky).  
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Figure 4.6 Protocol 2 for SVF differentiation 
 
 
A) SVF cells were isolated from 1-month-old male C57BL/6 mice, and 
differentiated following the Protocol 2 described in Chapter 2. When 90% 
confluent, cells were incubated for 2 days in culture media supplemented 
with 0.1 µM insulin, 1 µM dexamethasone, and 0.5 mM IBMX. Cells were 
subsequently incubated for an additional 2 days in culture media 
containing 0.1µM insulin, and then maintained in culture media without 
supplementation for another 3 days. 
B) SVF cells were isolated from 4-month-old male C57BL/6 mice and 
differentiated using media described in (A). 
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Figure 4.7 TG measurements in SVF adipocytes 
 
 
 
 
 
SVF isolated from 1-month-old and 4-month-old mice were differentiated using 
Protocol 2, as described in Chapter 2. On day 7, lipid was extracted. TG was 
quantified and normalized to cellular protein. ***P<0.001. 
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Figure 4.8 Induction of adipogenic genes in SVF 
 
 
 
SVF from 1-month-old mice were differentiated into adipocytes using Protocol 2. 
During differentiation, SVF cells were collected on day 0, day 3 and day 7 for 
RNA extraction. Adipogenic genes, PPARγ and aP2, were quantified by real time 
RT-PCR. **P<0.01, ***P<0.001. 
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Figure 4.9 Structure of isoproterenol and forskolin 
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Figure 4.10 Lipolysis response in the adipocytes derived from OP9, 3T3-L1 and 
SVF 
 
 
 
Differentiated OP9 (A), 3T3-L1 (B) and SVF (C) adipocytes were treated with 10 
µM isoproterenol or 20 µM forskolin. An aliquot of medium was collected to 
measure glycerol release. *P<0.05, ***P<0.001.  
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Figure 4.11 HSL Phosphorylation in 3T3-L1 and OP9 adipocytes 
 
 
 
After treating 3T3-L1 or OP9 adipocytes with isoproterenol or forskolin for 30 min, 
cellular protein was collected and blotted with anti-p660 HSL and total HSL 
antibody.  
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Figure 4.12 Immunofluoresence staining for p660-HSL in 3T3-L1 adipocytes 
 
 
Differentiated 3T3-L1 adipocytes were replated on cover glasses. After treating 
the cells with isoproterenol or forskolin for 30 min, cells were fixed and stained 
with anti-p660 HSL antibody (red) to monitor the phosphorylation and 
translocation of HSL in 3T3-L1 adipocytes after treatment with different lipolytic 
stimuli. Intracellular neutral lipid was stained with bodipy (green). Nuclei were 
stained with Dapi (purple).  
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Figure 4.13 Immunofluoresence staining for p660-HSL in OP9 adipocytes 
 
 
Differentiated OP9 adipocytes were replated on cover glasses. After treating the 
cells with isoproterenol or forskolin for 30 min, cells were fixed and stained with 
anti-p660 HSL antibody (red) to monitor the phosphorylation and translocation of 
HSL in OP9 adipocytes after treatment with different lipolytic stimuli. Intracellular 
neutral lipid was stained with bodipy (green). Nuclei were stained with Dapi 
(purple).   
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Figure 4.14 Expression of ADPrf6 in OP9 and 3T3-L1 adipocytes 
 
RNA was collected from differentiated 3T3-L1 (day 8) and OP9 (day 4) 
adipocytes and the expression of ap2 and ADPrf6 was measured.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Xia Li 2010 
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CHAPTER 5 
 
GX sPLA2 regulates TG accumulation in OP9 adipocytes 
 
Introduction 
Study in our laboratory has indicated that Group X secretory phospholipase 
A2 (GX sPLA2) is widely expressed in various tissues in mouse, including adipose 
tissues (Fig 1.3); however, the role of GX sPLA2 in adipose tissue is not known. 
The phenotype of Group X secretory phospholipase A2 (GX sPLA2) deficient (GX-
/-) mice with increased body weight and adiposity prompted us to define the role 
of GX sPLA2 in adipocytes.  
As described in Chapter 3, I have determined that OP9 cells provide many 
advantages for studies of adipogenesis, including easier handling, differentiation 
and transfection. Therefore, I have chosen OP9 cells in most of studies as a 
model of adipogenesis to manipulate the expression of GX sPLA2. The first 
approach is to add purified recombinant GX sPLA2 (obtained from Dr. Michael 
Gelb, University of Washington at Seattle) into the culture medium during OP9 
differentiation. The second approach is to overexpress GX sPLA2 in OP9 
preadipocytes. Due to the low transfection efficiency, transfected cells were 
maintained in medium containing G418 for stable selection. For the third 
approach, in addition to gain-of-function studies, I have also performed loss-of-
function studies to investigate the effect of the inhibitor of sPLA2, Me-indoxam 
(obtained from Dr. Michael Gelb, University of Washington at Seattle) on 
adipogenesis in OP9 cells overexpressing GX sPLA2. Due to the low expression 
of GX sPLA2 in adipocytes, it was difficult to knockdown the exogenous 
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expression of GX sPLA2. Therefore, siRNA was not included in the study of loss-
of-function of GX sPLA2 in adipocytes. 
GX sPLA2 is a secreted enzyme, which primarily acts on extracellular 
targets. However, there is evidence that GX sPLA2 may also hydrolyze 
intracellular targets prior to its secretion [39]. GX sPLA2 may also be internalized 
by the cells, possibly through interaction with M-type receptor, which GX sPLA2 
binds with high affinity [2]. In addition to its hydrolytic activity, some of the 
biological effects of GX sPLA2 were found to be independent of its catalytic 
activity [45], which may also involve the interaction with M-type receptor. An 
inactive mutant of GX sPLA2, H46Q, has a single site mutation that blunts its 
catalytic activity, without altering its affinity to bind on the M-type receptor [205]. 
Therefore, in the studies using OP9 cells transfected with wild type or inactive 
mutant H46Q, I examined whether the effect of GX sPLA2 in regulating 
adipogenesis is related to its catalytic activity and binding to M-type receptor.  
We had the novel finding that GX sPLA2 plays a regulatory role in 
adipogenesis. In the studies listed in this chapter, I investigated whether 
manipulating GX sPLA2 activity / expression had any effect in in vitro models of 
adipogenesis, including TG accumulation, TG synthesis and adipocyte-specific 
gene expression. With these different approaches of manipulating GX sPLA2, I 
have also investigated whether the role of GX sPLA2 in adipocytes is 1) 
dependent on its catalytic activity and 2) in an autocrine or paracrine manner. 
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Results 
GX sPLA2 and M-type receptor are expressed in OP9 
In order to investigate the role of GX sPLA2 in adipogenesis in OP9 cells, 
I firstly examined the mRNA expression of GX sPLA2 during differentiation. As 
previously described, when incubated with adipogenic stimuli, OP9 
preadipocytes were effectively differentiated into mature adipocytes as evidenced 
by the accumulation of lipid droplets and the upregulation of PPAR-γ and aP2, 
key transcription factors that drive adipocyte differentiation. GX sPLA2 mRNA 
was detected in OP9 preadipocytes and its expression was not significantly 
altered during differentiation (Fig 5.1 A). The transmembrane receptor, M-type 
receptor, which GX sPLA2 binds with high affinity, was also detected in OP9 cells 
throughout differentiation (Fig 5.1 B). GX sPLA2 mRNA was similarly detected in 
3T3-L1 cells before and after adipocyte differentiation (data not shown). 
Consistent with the result from differentiation of stromal vascular fraction (SVF), 
the expression of GX sPLA2 was not significantly altered during the differentiation 
of OP9 and 3T3-L1. Thus, OP9 and 3T3-L1 can both be used as in vitro models 
to define the role of GX sPLA2 in adipogenesis.  
TG accumulation and adipogenic genes were modestly decreased by addition 
of purified recombinant mouse GX sPLA2 
Various doses of GX sPLA2 were added into the medium during each day of 
OP9 differentiation. Based on Oil Red O staining, TG accumulation in OP9 cells with 
addition of GX sPLA2 was modestly decreased on a dose-dependent manner (Fig 
5.2), especially when doses exceeded 50 ng/mL. For the OP9 cells treated with 50 
ng/mL of GX sPLA2, cells were collected on day 0, day 1 and day 2 for RNA 
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extraction, followed by real time RT-PCR to analyze the induction of adipogenic 
genes. In GX sPLA2 treated OP9 cells, the induction of PPARγ and aP2 were both 
reduced (Fig 5.3). In this experiment, I have also noticed a reduction of cellular 
protein in the cells treated with recombinant GX sPLA2 (data not shown), which 
indicates the possible non-specific effects of purified recombinant enzyme.  
Lipid biosynthesis was not affected by exogenous GX sPLA2 
In order to examine whether exogenous GX sPLA2 affects lipid biosynthesis in 
OP9 cells, the rate of 3H-oleate incorporation was measured in OP9 preadipocytes 
treated with purified recombinant mouse GX sPLA2 in the presence of 0.6 mM E600, 
which had been previously shown to block lipolysis in 3T3-L1 cells [206]. We 
confirmed that lipolysis is inhibited in E600-treated OP9 cells for at least 6 h (Fig 5.4). 
Based on Oil Red O staining, GX sPLA2 with doses higher than 50 ng/mL mediates 
more pronounced reduction in TG accumulation in OP9 adipocytes (Fig 5.4). Thus, I 
have chosen 100 ng/mL of mouse GX sPLA2 in my preliminary study. As previously 
mentioned, some of the biological activities are through interaction with M-type 
receptor, and M-type receptor was detected in OP9 cells (Fig 5.1 B). It was of 
interest to examine whether M-type receptor is involved in the effect mediated by 
exogenous addition of GX sPLA2. Since sPLA2’s binding to M-type receptor is shown 
to be species specific, 100 ng/mL human GX sPLA2 was included as a control [239]. 
At one day post confluence, cells were treated overnight with delipidated medium 
supplemented with 100 ng/mL mouse or human GX sPLA2. On the next day, the 
incorporation of 3H-oleate into TG, DAG and PC was measured in OP9 cells in the 
presence of 0.6 mM E600, along with 100 ng/mL either mouse or human GX sPLA2 
for 4 h. No difference in any of lipid examined was observed in the cells treated with 
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human or mouse GX sPLA2 (Fig 5.5).  
Establishing stably transfected OP9 cell lines 
To study the role of GX sPLA2 in adipogenesis, I have established stably 
transfected cell lines OP9-GX or OP9-H46Q, and OP9-C, as described in 
Chapter 2. H46Q has a single site mutation on GX sPLA2, which blunts its 
catalytic activity [205]. Gene expression analysis indicated that, in both OP9-GX 
and OP9-H46Q preadipocytes, GX sPLA2 mRNA was increased for 80-100 folds 
(Fig 5.6 A). 48 h conditioned media were collected from OP9-C, OP9-H46Q and 
OP9-GX cells, and their sPLA2 activities were examined and normalized to 
cellular protein. OP9-GX preadipocytes secreted ~80% more phospholipase 
activity into the media compared to OP9-H46Q and OP9-C cells (Fig 5.6 B). To 
examine whether GX sPLA2 is expressed intracellularly, formaldehyde fixed OP9 
cells were stained with anti-Flag (Fig 5.7 A) or anti-GX sPLA2 (Fig 5.7 B) primary 
antibodies, followed by Alexa-conjugated secondary antibodies to visualize GX 
sPLA2 protein using confocal immunofluorescence microscopy. Intense 
fluorescence signal was detected in OP9-GX cells compared to OP9-C cells (Fig 
5.7 B). In order to investigate whether GX sPLA2 is associated with lipid droplets 
in adipocytes, differentiated OP9 adipocytes were treated with lipolytic stimuli, 
isoproterenol and forskolin, followed by co-staining with p-Ser660 HSL and Flag 
antibodies. In contrast with pHSL, which translocates to lipid droplets after being 
treated with forskolin, under any of the conditions, GX sPLA2 remains in the 
cytosol (Fig 5.8). 
OP9-GX had significantly reduced TG accumulation after differentiation 
When incubated under conditions that induce adipocyte differentiation, 
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OP9-GX cells, but not OP9-H46Q cells, accumulated significantly less TG 
compared to OP9-C cells as evidenced by oil red O staining (Fig 5.9) and 
biochemical determinations of cellular TG (Fig 5.10). Thus, the ability of GX 
sPLA2 to decrease TG accumulation in OP9 adipocytes was consistent with the 
effect of GX sPLA2 deficiency in vivo, where adipocyte TG accumulation was 
significantly increased. This result indicated that the constitutive overexpression 
of GX sPLA2 in OP9 cells has more pronounced effect of reducing TG 
accumulation than acute addition of GX sPLA2.  
The induction of adipogenic genes is reduced in OP9-GX cells  
We next investigated whether reduced TG synthesis in OP9-GX cells was 
accompanied by alterations in adipogenic gene expression. As described in Chapter 
1, PPARγ is the key regulator of adipogenesis, which targets the expression of aP2. 
Prior to adipocyte differentiation, the expression of PPARγ and aP2 was similar in 
OP9-C pre-adipocytes and OP9-GX pre-adipocytes (Fig 5.11). As expected, the 
expression of PPARγ and aP2 was significantly increased compared to baseline 
levels in OP9-C cells after treatment with adipogenic stimuli. Interestingly, the 
induction of PPARγ and aP2 was significantly blunted in OP9-GX cells compared to 
OP9-C cells after differentiation.   
Me-indoxam had little effect on TG accumulation in OP9 cells 
In order to examine the effect of inhibiting sPLA2 activity in adipogenesis in 
OP9 cells, at one day post confluence, OP9-C and OP9-GX were treated overnight 
with 1 ìg/mL of sPLA2 inhibitor, Me-indoxam. On the next day, cells were treated with 
differentiation medium for two days, followed by culture medium for another two days. 
During differentiation, 1 µg/mL of Me-indoxam or equal volume of vehicle (DMSO) 
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was added into the medium. At day 4, cells were stained with Oil Red O (Fig 5.12) or 
lipid was extracted for biochemical quantification (Fig 5.13). By either of the 
measurement, OP9-GX had significantly reduced lipid accumulation, compared to 
OP9-C; however, the effect of Me-indoxam treatment was not pronounced. On day 0 
and day 3, cells were collected for RNA extraction and gene expression analysis. No 
significant effect was observed with the treatment of Me-indoxam (Fig 5.14).  
 
Discussion 
In this chapter, I have demonstrated the three approaches I have used to 
manipulate the activity / expression of GX sPLA2 in OP9 cells. OP9 cells stably 
transfected with wild type GX sPLA2 had significantly reduced TG accumulation 
after differentiation, along with reduced induction of adipogenic gene expression. 
This effect was not observed in OP9 cells overexpressing catalytic inactive 
mutant, indicating the capacity of GX to reduce adipogenesis is dependent on its 
catalytic activity. In contrast, addition of recombinant GX failed to produce results 
as pronounced as stably transfected cells. Me-indoxam, a cell-impermeable 
sPLA2 inhibitor, did not reverse the effect of reduced TG accumulation mediated 
by GX sPLA2overexpression in OP9 cells.  
Overexpression in cells and adding exogenous protein in culture are both 
commonly used experimental approaches in laboratory studies; however, there 
are some obviously distinct features between the two treatments. Stable 
overexpression of GX sPLA2 generates preadipocytes that are constitutively 
secrete the enzyme, which may also have effect in its secretory pathway. 
However, there are several disadvantages about establishing the overexpression 
105 
 
preadipocytes. Firstly, it lacks the control for the amount of GX sPLA2 secreted 
into the medium. Secondly, due to the low transfection efficiency for 
preadipocytes, stable selection is required. During selection, cells are expected 
to become confluent, which may impair the adipogenic potential of 3T3-L1 cells. 
Fortunately, compared to 3T3-L1 cells, OP9 has the advantage of easier handling 
and differentiation (summarized in Chapter 3), which made the stable selection 
more plausible. In my experiments, no difference between OP9-C and regular 
untransfected OP9 cells was observed. In order to assure reproducibility, all the 
experiments comparing OP9-GX and OP9-C were repeated using three different 
sets of independently transfected cells. For all the experiments comparing OP9-
GX, OP9-H46Q and OP9-C, each experiment was repeated using two 
independently transfected lines. Interestingly, OP9-GX cells had significantly 
reduced TG accumulation after differentiation, compared to OP9-H46Q and OP9-
C (Fig 5.9, 5.10). The induction of adipogenic genes, PPARγ and aP2 were 
significantly blunted after differentiation, compared to OP9-C (Fig 5.11). These 
findings suggest that the effect of GX sPLA2 in adipocytes is dependent on its 
catalytic activity.  
In contrast, addition of purified recombinant enzyme may be manageable 
in term of the enzyme’s concentration in the medium; however, it lacks the effect 
on the secretory pathway. The action of the added enzymes may be through 
generating bioactive lipid mediators by directly hydrolyzing on the phospholipid 
layer on the extracellular leaflet. Moreover, GX sPLA2 may also mediate 
intracellular signaling by interacting with the transmembrane receptor, M-type 
receptor [45]. The mRNA of M-type receptor is detected in OP9 preadipocytes 
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and adipocytes (Fig 5.1 B); however, no study has suggested the role of M-type 
receptor in adipocytes. Based on our findings in OP9 cells, the effect of GX 
sPLA2 is unlikely to be through M-type receptor, since H46Q also binds on M-
type receptor [240], but it does not reproduce the same effect as wild type GX 
sPLA2 (Fig 5.9, 5.10). 
In studies using purified recombinant GX sPLA2, enzyme with various 
doses were added into OP9 preadipocytes during differentiation. Oil Red O 
staining indicates reduced TG accumulation in differentiated OP9 adipocytes in a 
dose-dependent manner (Fig 5.2). However, based on Oil Red O staining, the 
reduction on TG by recombinant enzyme is not as pronounced in OP9-GX. The 
inhibition of adipogenic gene induction, PPARγ and aP2 was also more 
pronounced in the overexpression system. Moreover, we have also observed the 
significant reduction in protein concentration in the cells differentiated in the 
presence of purified enzyme (data not shown). This may possibly indicates the 
recombinant enzyme’s non-specific effects to the cells, such as cytotoxicity, since 
the purified enzyme was produced by E. coli. In order to confirm the effect of 
modestly reduced TG by is specific to treatment of GX sPLA2, other recombinant 
sPLA2 enzymes, such as GIIA sPLA2 or GV sPLA2, may be included as controls.  
A few studies have suggested the hydrolytic activity of GX sPLA2 on 
intracellular targets during secretion [39]. The cell-impermeable inhibitor Me-
indoxam only partially blocks the increased release of AA by GX sPLA2 
overexpression. This effect was also observed for GIIA sPLA2. In OP9 adipocytes, 
OP9-GX had significantly reduced TG accumulation after differentiation, 
compared to OP9-C, and Me-indoxam was not effective in reversing the reduced 
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TG in OP9-GX. In addition, intracellular GX sPLA2 protein was detected using 
confocal immunofluorescence, which has also indicated the possible role of GX 
sPLA2 acting intracellularly in the adipocytes. It is not known whether intracellular 
GX sPLA2 represents newly synthesized GX that has not been released from 
cells, or secreted protein that has been taken up. Based on the 
immunofluorescene staining shown in Fig 5.8, compared to p-HSL, which is co-
localized to the lipid droplets when treated with forskolin; there is no evidence 
that GX sPLA2 is localized on the lipid droplets. In order to determine whether GX 
sPLA2 undergoes internalization, binding and uptake experiments using either 
fluorescently labeled or radiolabeled recombinant mouse GX sPLA2 can be 
performed.  
  The comparison between GX sPLA2 overexpression and addition of GX 
sPLA2 enzyme may also reveal whether GX sPLA2 is acting in an autocrine or 
paracrine manner. Our results tend to suggest that the GX sPLA2 produced by 
the adipocytes may have more pronounced effect, compared to the exogenous 
enzyme. However, the fractionation of mouse adipose tissue also indicates that 
GX sPLA2 is expressed in both SVF and adipocytes. We have not specifically 
studied which cell type in the SVF express GX sPLA2. Macrophage is known to 
secret GX sPLA2 [29], and obesity is associated with increased macrophage 
accumulation in the adipose tissue [241]. In order to investigate the role of 
macrophage-derived GX sPLA2 in adipose tissue in vivo, a bone marrow 
transplantation study may be required..  
 In summary, we have provided results for the role of GX sPLA2 on 
adipogenesis in OP9 cells, by three approaches to modulate the expression and 
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activity of GX sPLA2. Our data indicated that GX sPLA2 may likely regulate 
adipogenesis on an autocrine manner, rather than exogenous effect. Based on 
loss-of-function and gain-of-function studies in vitro we conclude that hydrolytic 
products generated by GX sPLA2 impede the adipogenic program. The reduced 
TG content may be due to reduced TG synthesis by the overexpression of GX 
sPLA2, rather than an enhanced rate of TG turnover. Future studies will address 
the effect of macrophage derived GX sPLA2 on adipose tissue formation in vivo 
and its metabolic consequences.  
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Figure 5.1 GX sPLA2 is expressed in OP9 and 3T3-L1 cells 
 
 
 
Cells were collected during differentiation of OP9 cells and RNA was extracted, 
followed by real time PCR to analyze the expression of GX sPLA2 (A) and M-type 
receptor (B). 
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Figure 5.2 Differentiation of OP9 cells in the presence of GX sPLA2 with various 
doses 
 
OP9 preadipocytes were treated with various indicated doses of GX sPLA2 
during differentiation. At the end of differentiation (day 4), cells were stained with 
oil red O to assess the accumulation of neutral lipid.  
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Figure 5.3 Induction of adipogenic genes in the presence of 50 ng/mL GX sPLA2 
 
 
OP9 was differentiated in the presence or absence of 50 ng/mL of GX sPLA2. On 
day 0, day 1 and day 2, cells were collected for RNA extraction, followed by real 
time RT-PCR to assess the induction of adipogenic genes, PPARγ and aP2. 
112 
 
Figure 5.4 The effectiveness of E600 to block lipolysis 
 
 
OP9 cells were labeled with 3H-oleate for 16 h, and then incubated with fresh 
fatty acid-deficient media containing 0.6 mM E600 or vehicle (DMSO). Cells were 
collected at the indicated time, and the amount of 3H-oleate incorporated into TG 
was determined. Data are the mean (± SE) of triplicate samples. ***P<0.001 
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Figure 5.5 The rate of lipid biosynthesis in OP9 with addition of 100 ng/mL 
purified recombinant human or mouse GX sPLA2 
 
 
After two days post-confluence, OP9 cells were incubated for 4 h with delipidated 
medium containing 3H-oleate, cold oleate complexed to BSA and E600, along 
with purified recombinant mouse GX sPLA2 and human GX sPLA2. The amount 
of 3H-oleate incorporated in TG (A), DAG (B) and PC (C) was determined by TLC 
in the solvent systems indicated in Chapter 2.  
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Figure 5.6 Gene expression and phospholipase A2 activities in stably transfected 
cells 
 
A 
 
B 
 
A) Stably transfected OP9 preadipocytes were collected for RNA extraction, 
followed by gene expression analysis.  
B) Phospholipase A2 activity assay was performed to measure the sPLA2 activity 
in 48h conditioned medium, and normalized by cellular protein.  ***P<0.001.  
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Figure 5.7 The expression of GX sPLA2 in OP9-GX 
 
A) OP9-GX was stained with anti-flag primary antibody, followed by Alexa 
488-conjugated secondary antibody, to detect the intracellular expression 
of GX-flag.  
B) OP9-GX and OP9-C were stained with anti-GX sPLA2 primary antibody 
and its depleted fraction (negative control), followed by Alexa 488-
conjugated secondary antibody, to detect the intracellular expression of 
GX sPLA2. 
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Figure 5.8 Intracellular localization of GX sPLA2 
 
 
 
Differentiated OP9-GX adipocytes were treated with isoproterenol or forskolin for 
30 min. Cells were fixed and co-stained with two antibodies, Flag (green) and p-
Ser660 HSL (red). Slides were mounted with Dapi (blue). 
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Figure 5.9 TG accumulation after differentiation in OP9-C, OP9-H46Q and OP9-
GX 
 
 
After differentiation (day 4), the accumulation of TG in the three cell lines was 
accessed by oil red O staining. 
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Figure 5.10 TG accumulation in OP9-C, OP9-H46Q and OP9-GX during 
differentiation 
 
At indicated day of differentiation, total lipid was extracted. TG was measured 
and normalized by cellular protein. ***P<0.001.  
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Figure 5.11 The induction of adipogenic genes in OP9-C and OP9-GX 
 
 
In OP9-C and OP9-GX, before and after differentiation, cells were collected for 
RNA extraction. Real time RT-PCR was performed to analyze the induction of 
adipogenic gene expression, PPARγ and aP2. **P<0.01, ***P<0.001.  
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Figure 5.12 Oil Red O staining for OP9 adipocytes differentiated in the presence 
of Me-indoxam 
 
 
At each day of differentiation, cells were treated with 1 µg/mL of Me-indoxam or 
vehicle control (DMSO). At the end of differentiation (day 4), cells were stained 
with oil red O to assess the TG content.  
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Figure 5.13 TG accumulation in OP9 adipocytes differentiated in the presence of 
Me-indoxam 
 
At the end of differentiation (day 4), total lipid was extracted. TG content was 
quantified and normalized to cellular protein. ***P<0.001 
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Figure 5.14 Induction of adipogenic genes in OP9 cells differentiated in the 
presence of Me-indoxam 
 
 
OP9 cells were collected at day 0 (before differentiation) and day 3 (after 
differentiation). RNA was extracted, followed by real time RT-PCR to assess the 
induction of adipogenic genes, PPARγ and aP2. 
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CHAPTER 6 
GX sPLA2 negatively regulates LXR activation and adipogenesis in murine 
adipocytes 
 
Introduction 
 The incidence of obesity is rapidly growing globally, with its prevalence 
reaching epidemic proportions particularly in Western countries. The excess 
expansion of adipose tissue markedly increases the risk of type II diabetes and 
cardiovascular complications [208]. However, lipodystrophy, the lack of adipose 
tissue, is also associated with insulin resistance and abnormal lipid metabolism 
[78, 217]. In addition to its role as a central modulator of lipid homeostasis and 
energy balance, adipose tissue is also an important endocrine organ, producing 
a variety of cytokines and adipokines that regulate whole body metabolic and 
inflammatory status [108, 216].  Thus, the factors that regulate the formation and 
function of adipose tissue are critically important to human health. 
 The expansion of white adipose tissue (WAT) results from two processes, 
the conversion of precursor cells into differentiated adipocytes (hyperplasia), and 
the growth of individual fat cells due to increased storage of triglycerides 
(hypertrophy). In the setting of obesity, the failure to appropriately respond to the 
need to store excess energy in adipose tissue may result in metabolic disorders 
[74-75]. Insights into the regulation of the adipogenic program at the molecular 
level may provide novel targets for manipulating the number of adipocytes and 
for ameliorating metabolic consequences of obesity. 
 The process of adipogenesis has been widely studied in vitro using well-
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characterized cell lines, including murine 3T3-L1 [222] and OP9 [204] 
preadipocyte cells.  The differentiation of fibroblast-like preadipocytes into mature 
adipocytes is carried out by a tightly regulated transcription cascade that 
coordinates the induction of lipogenic and adipocyte-specific genes. The 
transcription factors C/EBPs and PPARγ are considered the master regulators of 
adipocyte differentiation [125-127]. PPARγ, a member of the nuclear receptor 
family of ligand-activated receptors, has been shown to be indispensable for 
adipocyte differentiation. PPARγ forms a heterodimer with the RXR to interact 
with PPARγ response elements (PPREs) on adipocyte-specific genes [132-133]. 
Although PPARγ activation is critical for adipogenesis, accumulating evidence 
indicates that a number of other transcription factors can profoundly affect 
adipocyte differentiation, adipocyte-specific gene expression, and adipocyte lipid 
accumulation.  For example, SREBP-1c mRNA is induced 24 hours after the 
treatment of differentiation stimuli in 3T3-L1 cells [138]. Overexpression of 
SREBP-1c leads to enhanced adipogenesis, an effect that is PPARγ-dependent. 
Interestingly, overexpression of SREBP-1c in 3T3-L1 cells also induces the 
expression of PPARγ, indicating crosstalk between these two factors [139]. More 
recently, LXRE have been identified in the promoter region of PPARγ, linking the 
nuclear receptor LXR to adipogenesis [193]. Treatment with the LXR agonist 
T0901317 was shown to increase TG accumulation and enhance the induction of 
adipogenic /lipogenic genes, including PPARγ, aP2, SREBP1c and FAS in 3T3-
L1 cells [193].  Notably, mice deficient in LXRβ are   protected from diet or age-
induced obesity [200]. 
In this study, I report the novel finding that GX sPLA2 plays a regulatory 
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role in adipogenesis. GX sPLA2 is a member of the sPLA2 family of enzymes that 
has been implicated in a number of biological processes based on its potent 
ability to hydrolyze mammalian cell membranes [242-243]. Based on gain-of-
function studies in vitro I conclude that hydrolytic products generated by GX 
sPLA2 impede the adipogenic program.  I also provide evidence that this effect 
on adipogenesis is due, at least in part, to the suppression of LXR activation.  
 
Results 
TG turnover rate is not affected in OP9 cells overexpressing GX sPLA2 
In previous chapter, I have shown that OP9 cells with stable overexpression 
of GX sPLA2 (OP9-GX) had significantly reduced TG accumulation after 
differentiation, compared to OP9 cells stably transfected with control expression 
vector (OP9-C). Then I investigated whether the reduced TG accumulation in OP9-
GX cells was due to decreased TG synthesis or enhanced TG lipolysis. I firstly 
examined whether the TG turnover rate was different between OP9-C and OP9-GX. 
After two days post-confluence, 3H-oleate was incorporated into OP9-GX and OP9-C 
cells for 16 h. Fresh medium with no supplementation of FFA was added, in the 
presence of triacsin C to block FFA re-esterification. Cells were collected at indicated 
intervals to assess the remaining 3H-oleate incorporated TG pool in OP9-GX and 
OP9-C cells. Interestingly, there was a dramatic difference in 3H-oleate labeled TG 
the starting point (0 h) between OP9-C and OP9-GX (Fig 6.1 A). This indicates that 
3H-oleate incorporated into TG in OP9-GX during 16-h labeling period was 
remarkably less than OP9-C. To compare the rate of TG turnover, the amount of 
remaining 3H-oleate incorporated TG was normalized as the percentage to baseline 
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(starting point, 0 h) (Fig 6.1 B). There was no evidence that the rate of turnover of 
the 3H-oleate-labeled TG pool was significantly different between OP9-C and OP9-
GX cells. Thus, the reduced TG accumulation in OP9-GX after differentiation is not 
due to enhanced lipolysis. However, the rate of TG synthesis may be affected in 
OP9-GX. 
TG synthesis is significantly reduced in OP9-GX 
To assess TG synthesis rate, the incorporation of 3H-oleate into TG was 
measured in OP9-C, OP9-H46Q and OP9-GX cells in the presence of 0.6 mM E600, 
which I have confirmed to block lipolysis in OP9 cells (Fig 5.4). Compared to OP9-C 
and OP9-H46Q cells, OP9-GX cells incorporated significantly less 3H-oleate into 
triglyceride during a 4-h labeling period, indicating that TG synthesis is reduced in 
OP9-GX cells (Fig 6.2). Thus, GX sPLA2 appears to reduce TG accumulation in OP9 
cells by blunting lipogenesis rather than enhancing lipolysis. On the other hand, the 
incorporation of 3H-oleate into DAG and PC was not significantly different between 
OP9-GX and OP9-C cells (Fig 6.2). 
The induction of adipogenic genes is reduced in OP9-GX cells 
In Chapter 4, I have shown that OP9-GX had significantly reduced TG 
accumulation after differentiation, reduced adipogenic markers, PPARγ and aP2, as 
well as reduced TG synthesis, compared to OP9-C. I next investigated whether 
reduced TG synthesis in OP9-GX cells was accompanied by alterations in lipogenic 
gene expression. Prior to adipocyte differentiation, the expression of SREBP-1c was 
significantly lower in OP9-GX cells compared to OP9-C cells (Fig 6.3). Expression of 
the remaining genes examined, diacylglycerol O-acyltransferase 1 (DGAT1), FAS, 
and stearoyl-coenzyme A desaturase 1 (SCD1) was similar in OP9-C pre-adipocytes 
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and OP9-GX pre-adipocytes. As expected, the expression of each of these genes 
was significantly increased compared to baseline levels in OP9-C cells after 
treatment with adipogenic stimuli. Interestingly, the induction of all of the genes 
examined was significantly blunted in OP9-GX cells compared to OP9-C cells.  The 
effect of GX sPLA2 to lower adipogenic gene expression was most pronounced for 
SREBP-1c, FAS, and SCD1 where expression was reduced 70-80% compared to 
control values. 
The adipogenic effect of the LXR agonist T0901317 is reduced in OP9-GX cells 
compared to OP9-C cells 
Studies in our laboratory have demonstrated that hydrolytic products 
generated by GX sPLA2 block the activation of LXR (P. Shridas et al. in revision). 
This finding is in keeping with other studies showing that polyunsaturated fatty acids, 
especially AA, block LXR-mediated gene induction [156] [244]. Given that SREBP-1c, 
SCD1 and FAS are known LXR targets [153, 164-165], and LXR activation promotes 
adipogenesis and increases TG accumulation in adipocytes [192-193], I investigated 
the possibility that GX sPLA2 reduces TG accumulation in OP9 cells by suppressing 
LXR activation. OP9-C and OP9-GX cells were differentiated in the presence or 
absence of 5 µM T0901317 and markers of adipogenesis were assessed. As 
published previously for 3T3-L1 cells and human primary preadipocytes [192-194], 
addition of the LXR agonist during 2 days of differentiation significantly increased TG 
accumulation in OP9-C cells (Fig 6.4). This effect was totally abolished in cells 
overexpressing GX sPLA2 (Fig 6.4).  Furthermore, the ability of LXR agonist to 
increase the expression of adipogenic genes was significantly blunted in OP-GX 
cells (Fig 6.5 A-C).  Interestingly, T0901317 treatment did not result in an enhanced 
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induction of PPARγ during the differentiation of either OP9-C or OP9-GX cells (Fig 
6.5 D), in contrast to what has been shown in 3T3-L1 cells [193]. This lack of effect 
of the LXR agonist may be due to the fact that OP9 cells are at a later stage of 
adipocyte differentiation compared to 3T3-L1 cells, and express PPARγ even in the 
absence of adipogenic stimuli [204]. In the case of 3T3-L1 cells, LXR agonists failed 
to have an effect on PPARγ expression at a later stage of differentiation [193]. Taken 
together, I interpret my results to suggest that GX sPLA2 reduces TG accumulation 
in adipocytes by suppressing the adipogenic effect of LXR. 
GX sPLA2 overexpression reduces LXR luciferase reporter activity in 
adipocytes 
In order to examine directly the effect of GX sPLA2 on LXR activity in 
adipocytes, 3T3-L1 and OP9 preadipocytes were co-transfected with mouse LXRα, 
a luciferase reporter construct containing a synthetic LXRE, renilla luciferase, along 
with GX sPLA2 or control expression vector. One day after transfection, cells were 
treated with 5 µM T0901317 or vehicle control. In the absence of LXR agonist, 3T3-
L1 and OP9 cells overexpressing GX sPLA2 exhibited reduced LXRE promoter 
activity compared to their corresponding controls (Fig 6.6 A, B). Addition of agonist 
failed to activate reporter activity in 3T3-L1 and OP9 cells overexpressing GX sPLA2 
to the same extent as their corresponding control cells. These findings were 
confirmed in additional experiments whereby GX sPLA2 was stably expressed in 
3T3-L1 and OP-9 cells (Fig 6.7 A, B). 
 
Discussion 
 As described in previous chapter, OP9 cells stably transfected with GX 
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sPLA2 cDNA accumulated significantly less TG during differentiation compared to 
control cells, consistent with the conclusion that GX sPLA2 negatively regulates 
the capacity of adipocytes to store fat. The effect of GX sPLA2 on TG 
accumulation was not observed in OP9 cells overexpressing H46Q, a mutated 
variant lacking catalytic activity.  There was no evidence that the rate of lipolysis 
was altered by GX sPLA2. The incorporation of 3H-oleate into triglyceride was 
significantly reduced in OP9-GX cells compared to control cells, indicating that GX 
sPLA2 overexpression results in reduced lipogenesis.  Additional studies showed 
that GX sPLA2 affects the incorporation of free fatty acids (FFA) into the TG pool 
but not overall utilization of FFA for PC or DAG synthesis. . 
I also showed that GX sPLA2 overexpression leads to significantly reduced 
expression of adipogenic genes, including PPARγ, SREBP-1c, FAS, and SCD1 in 
OP9 adipocytes. The master regulators in adipogenesis are transcription factors 
CCAAT/enhancer binding proteins (C/EBPs) and peroxisome proliferator-
activated receptor γ (PPARγ)[125-127]. PPARγ is highly upregulated during 
adipocyte differentiation, which is induced by C/EBPβ, and δ [131]. Extensive 
investigations have established the role of PPARγ in adipogenesis and adipocyte 
function [245-246]. Activation of PPARγ in preadipocytes initiates a transcriptional 
cascade that signals the cells to differentiate and acquire the full range of 
adipocyte functions, including the ability to produce TG from FFA derived either 
from circulating lipoproteins or de novo lipogenesis. In the case of OP9 
preadipocytes, PPARγ expression is readily detected in cells grown to confluence, 
indicating that the adipogenic differentiation program is already underway [204]. 
When confluent OP9 cells are exposed to the appropriate stimuli, PPARγ is 
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rapidly induced, and the cells acquire the morphology and adipocyte marker 
protein expression of mature adipocytes [204]. GX sPLA2 appears to inhibit TG 
accumulation by interfering with the adipogenic program. Therefore, in addition to 
the genes listed in Chapter 5 and Chapter 6, the expression of other key 
regulators, such C/EBPs, may also need to be examined.  
A role for LXRs in adipogenesis has also been investigated in a number of 
studies. In the liver, LXRs modify the expression of lipogenic genes such as FAS 
either through direct interactions with the target gene promoter [153] or by 
regulating SREBP1c expression [165-166]. Both LXRα and LXRβ are highly 
expressed in adipose tissue, where they appear to regulate distinct sets of 
adipocyte genes [247]. LXRα expression is induced by PPARγ during adipocyte 
differentiation, whereas LXRβ expression remains relatively constant [191-193].  
According to some reports, PPARγ is a target of LXR, and activation of LXR 
stimulates adipocyte differentiation by upregulating PPARγ expression [193].  
Thus, LXR has been proposed to function in adipocyte differentiation by 
promoting the expression of both adipocyte-specific genes (through PPARγ) and 
lipogenic genes (directly, or through SREBP-1c).  However, a subsequent 
investigation in human adipocytes indicated that LXR activation promotes TG 
accumulation by strongly stimulating SREBP-1c and lipogenic gene expression 
without activating the differentiation process through PPARγ [194]; other 
published studies have reported no role for LXR in mediating adipogenesis [191] 
[196].   In our studies, the LXR agonist T0901317 resulted in significantly 
increased TG accumulation in differentiating mouse OP9 cells (Fig 6.4).  This 
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effect was accompanied by a significant upregulation of the lipogenic genes 
SREBP-1c, FAS, and SCD1, but no change in PPARγ expression in cells after 1 
day of differentiation (Fig 6.5). Notably, GX sPLA2 overexpression markedly 
reduced the effect of LXR agonist to enhance TG accumulation and adipogenic 
gene expression during OP9 adipocyte differentiation.    
Our results from synthetic LXR promoter luciferase constructs provide 
evidence that GX sPLA2 may negatively regulate adipogenesis by inhibiting the 
ability of LXR to trans-activate its target promoters. Consistent with our 
conclusion that GX sPLA2 suppresses LXR, the phenotype of GX-/- mice 
(adipocyte hypertrophy) is opposite to LXRβ-deficient mice, which are resistant to 
the increase in adipocyte size associated with aging or high fat diet feeding [200].  
I speculate from our data that hydrolytic products generated by GX sPLA2, most 
likely AA, suppress the expression of LXR target genes including SREPB-1c in 
adipocytes by negatively regulating LXR activation. This conclusion is in keeping 
with other studies showing that polyunsaturated fatty acids, especially AA, block 
LXR-mediated gene induction [156] [244]. Gel shift mobility and ligand binding 
domain activation assays indicate that AA competes with LXR agonists to block 
LXR activation [156]. 
In a recent study it was reported that oral administration of the non-
selective PLA2 inhibitor methyl indoxam suppressed diet-induced obesity and 
glucose intolerance in C57BL/6 mice [248].  The authors interpreted this effect to 
the inhibition of group 1B phospholipase A2 (GIB sPLA2) in the intestinal lumen. 
GIB sPLA2 is a pancreatic enzyme that contributes to diabetes and obesity by 
generating the digestive product lysophospholipid, which when absorbed 
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postprandially contributes directly to glucose intolerance and hyperglycemia [249]. 
Our findings with GX sPLA2 are in interesting contrast to recent studies 
investigating another adipocyte-expressed phospholipase A2, AdPLA. AdPLA is a 
membrane-associated intracellular PLA2 that is highly enriched in WAT and 
induced during adipocyte differentiation [250]. AdPLA-deficient mice have 
significantly reduced adipose tissue mass and TG content but apparently normal 
adipogenesis.  The phenotype of AdPLA-deficient mice was attributed to 
increased lipolysis in adipose tissue through a mechanism involving the 
downstream AA metabolite prostaglandin E2 [231].  In the current study I provide 
strong evidence that GX sPLA2, through a different mechanism, negatively 
regulates the adipogenic program and suppresses the ability of adipocytes to 
store lipid.  Future studies will define the role of GX sPLA2 in the metabolic 
consequences of obesity. 
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Figure 6.1 The rate of TG turnover in OP9-C and OP9-GX cells 
 
 
A) After two days post confluent, OP9-C and OP-GX were incubated in 
delipidated medium supplemented with 3H-oleic acid for 16 h. The labeling 
medium was then replaced with fresh delipidated medium containing 6 µM 
triacsin C to block fatty acid re-esterification. Cells were collected at 
indicated intervals up to 32 h. Lipid was extracted and the remaining 3H-
oleate incorporated into TG was quantified. 
B)  The data in (A) were all normalized to their corresponding baseline values 
(0 h) in OP9-C and OP9-GX.  
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Figure 6.2 The rate of lipid biosynthesis in stably transfected OP9 cells 
 
 
 
 
After two days post-confluence, transfected OP9 cells were incubated for 4 h with 
delipidated medium containing 3H-oleate, cold oleate complexed to BSA and 
E600. The amount of 3H-oleate incorporated in TG, DAG and PC was determined 
by TLC in the solvent systems indicated in Chapter 2. 
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Figure 6.3 The induction of adipogenic genes is reduced in OP9-GX cells 
 
 
RNA was isolated from OP9-C and OP9-GX cells either before (day 0) or after 
(day 3) differentiation. Real time RT-PCR was performed using primers specific 
for the indicated genes. Data are means (± SE) of triplicate samples and are 
representative of 3 independent experiments. * P<0.05, ** P<0.01, *** P<0.001. 
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Figure 6.4 LXR agonist T0901317 increased TG accumulation in OP9-C, but not 
in OP9-GX 
 
OP9-C and OP9-GX cells were incubated in differentiation media supplemented with 
5 µM T0901307 or vehicle. After two days, cellular lipid was extracted, and cellular 
TG content, normalized to cellular protein, was determined. 
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Figure 6.5 LXR agonist T0901317 induced lipogenic gene expression in OP9-C, 
but not in OP9-GX 
 
RNA was collected at day 1 of differentiation and the expression of adipogenic 
genes was quantified by real time RT-PCR. Data are means (± SE) of triplicate 
samples and are representative of two independent experiments. * P<0.05, ** 
P<0.01, *** P<0.001. 
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Figure 6.6 Reporter activity in transiently transfected 3T3-L1 and OP9 cells.  
 
 
A) 3T3-L1 cells were transiently transfected with plasmids encoding pTK-
3xLXRE-Luc, mLXRα and renilla luciferase, along with an empty vector 
expression plasmid (C) or an expression plasmid encoding GX sPLA2 (GX). 
Luciferase activity was measured and presented as values after normalization 
with renilla luciferase activity. Data are the mean (± SE) of triplicate samples and 
are representative of 3 independent experiments.  
B) OP9 cells were transfected with plasmids listed in (A). Luciferase activity was 
measured and normalized to renilla. Results were confirmed using stably 
transfected preadipocytes (Supplemental Fig. S7). Data are the mean (± SE) of 
triplicate samples. **P < 0.01, ***P<0.001.  
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Figure 6.7 LXRE reporter activity is reduced in 3T3-L1 and OP9 cells 
overexpressing GX sPLA2:  
 
 
A) 3T3-L1 stably transfected with control plasmid (3T3-C) or GX sPLA2 (3T3-GX) 
were transiently transfected with plasmids encoding pTK-3xLXRE-Luc, mLXRα 
and renilla luciferase. Luciferase activity was measured and presented as values 
after normalization with renilla luciferase activity.  
B) OP9-C and OP9-GX were transfected with plasmids listed in (A). Luciferase 
activity was measured and normalized to renilla. Data are presented as mean (± 
SE) of triplicate samples and are representative of 2 independent experiments. 
*P<0.05, **P < 0.01, ***P<0.001.   
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CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
In recent years, obesity has emerged as a global health problem. 
According to WHO’s estimation, by 2015, the number of adult people being 
overweight (BMI > 25 kg/m2) is expected to reach 2.3 billion worldwide, with 700 
million being obese (BMI > 30 kg/m2). Obesity is a multi-factor disease, including 
both intrinsic and extrinsic factors, such as genetics, diet and life styles. The 
excess of adipose tissue in obesity is associated with increased risk for metabolic 
diseases, such as hypertension, type II diabetes and cardiovascular 
complications [208]. In addition to its role in modulating lipid homeostasis and 
energy balance, adipose tissue is also an important endocrine organ, producing 
a variety of cytokines and adipokines that regulate whole body metabolic and 
inflammatory status [108, 251].  
Understanding the process of adipose tissue formation involves the 
investigation into adipogenesis and triglyceride (TG) synthesis / mobilization. 
Genetically engineered mice and manipulating gene expression in preadipocytes 
cell lines or primary preadipocytes are useful tools in studying adipocyte biology. 
In my study, I have demonstrated the utility of several gain-of-function and loss-
of-function systems to manipulate gene expression in adipocytes and 
investigated the consequence in adipogenesis, TG synthesis and lipolysis. With 
these approaches, I have demonstrated the role of Group X secretory 
phospholipase A2 (GX sPLA2) in mouse model of obesity. My data suggests that 
GX sPLA2 negatively regulates adipogenesis and TG synthesis in adipocytes, 
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possibly through suppressing nuclear receptor LXR activities.  
My study was initiated by the interesting phenotype in mice deficient in GX 
sPLA2 (GX-/-). GX-/- mice have increased body weight and adiposity, even on 
regular diet feeding. Although our work did not specifically address gender 
differences, both male and female GX-/- mice exhibited a similar trend for 
increased body weight and adiposity, compared to their corresponding control 
mice. In my study, the data were generated using male mice. The higher body 
weight in GX-/- mice becomes more pronounced as the mice aged; however, at a 
relatively younger age, the phenotype of increased adiposity occurs before an 
increase in body weight is detected. Interestingly, the increased adiposity and 
body weight is not accompanied by altered amount of food consumption or 
energy expenditure. Preliminary study also demonstrated that, at least for one 
set of study, chow diet fed GX-/- mice have increased adipose tissue macrophage 
(ATM) infiltration, compared to C57BL/6 mice. This may be a consequence of 
increased adiposity in GX-/- mice. However, in high fat diet fed mice, although the 
increased adipocyte hypertrophy became even more pronounced, this difference 
in ATM content was not observed. Indeed, there was a non-significant trend for 
decreased ATMs in GX-/- mice, compared to the control mice. This finding is 
possibly associated with another preliminary observation in our laboratory that 
GX-/- mice are protected from high fat diet induced insulin resistance. More 
studies are needed to investigate the molecular mechanism for the improved 
insulin sensitivity in GX-/- mice.  
In my study, I have focused on in vitro culture systems to investigate how 
GX sPLA2 regulates TG homeostasis in adipocytes. In Chapter 4, I have 
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summarized the advantages and disadvantages of three in vitro systems in my 
study, 3T3-L1, OP9 and primary stromal vascular fraction (SVF) isolated from the 
mice. I have found that GX sPLA2 is expressed in these cells before and after 
adipocyte differentiation. SVF isolated from GX+/+ and GX-/- provides a loss-of-
function model to investigate the effect of GX sPLA2 deficiency in TG 
accumulation in adipocytes. For gain-of-function manipulation, due to the 
advantages of easier handling, differentiation and cDNA transfection, OP9 cells 
were used in most of the in vitro studies, including adipocyte differentiation, gene 
expression and luciferase promoter activity assays.  
To study the role of GX sPLA2 in OP9 cells, I have used several 
approaches, including addition of purified recombinant GX sPLA2, inhibiting 
enzymatic activity secreted into the medium using a cell-impermeable inhibitor, 
Me-indoxam, and stably overexpressing cell lines. As demonstrated in Chapter 4, 
stable GX sPLA2 overexpression in OP9 cells led to reduced TG accumulation, 
which is consistent with our observation that mice deficient in GX sPLA2 exhibit 
adipocyte hypertrophy in vivo. Addition of recombinant GX sPLA2 during OP9 
differentiation reduced TG accumulation, based on Oil Red O staining; however, 
the effect was not as pronounced as constitutive stable overexpression. Inhibiting 
the extracellular activity of GX sPLA2 in the medium by Me-indoxam failed to 
reverse the effect of GX sPLA2 overexpression.  This may indicate that, in 
addition to the extracellular hydrolytic activity of GX sPLA2, the intracellular GX 
sPLA2 may also have an effect on TG accumulation in OP9 cells.  
I have established stably transfected OP9 cells with overexpression of wild 
type (OP9-GX) and catalytic inactive mutant of GX sPLA2 (OP9-H46Q). Control 
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cells were stably transfected with empty expression vector (OP9-C). By gene 
expression analysis, both OP9-GX and OP9-H46Q showed 80-100 fold increase 
in mRNA of GX sPLA2, compared to OP9-C. However, the phospholipase activity 
secreted into the medium was increased only 80% for OP9-GX compared to 
OP9-C or OP9-H46Q cells. Due to the low expression of GX sPLA2 in OP9 cells 
and the sensitivity of western blot, using anti-GX antibody failed to detect the 
secretion of GX sPLA2 into the media. This could be due to the lack of secretion 
of the overexpressed enzyme or extracellular degradation. Additionally, as 
previously reported, GX sPLA2 may remain as an inactive pre-pro-peptide, which 
needs to undergo proteolytic cleavage to become fully active [53]. The lack of 
enzymatic activity may also be due to lack of this activation cleavage after 
secretion.  Interestingly, immunofluorescence staining showed abundant 
intracellular expression of GX sPLA2 in OP9-GX cells, which may related to my 
findings that exogenous addition of recombinant enzyme or Me-indoxam had little 
effect on OP9 adipogenesis. It is possible that intracellular GX sPLA2 may 
participate in the regulation of TG storage.  
The amount of TG storage in adipocytes can be influenced by several 
factors, including TG synthesis and mobilization.  Studies in our laboratory 
showed that adipose tissue collected from GX-/- mice exhibited a reduced rate of 
basal and isoproterenol-stimulated lipolysis ex vivo (data not shown). However, 
we do not know whether the reduced lipolysis is due to a primary lipolytic defect 
in the GX-/- adipose tissue, which led to increased TG storage. On the other hand, 
the amount of TG storage may also affect the efficiency of lipolysis. For example, 
adipocytes lacking FSP27 form multilocular lipid droplets and decreased TG 
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storage, which leads to increased basal lipolysis [98, 252]. This enhanced 
lipolysis was possibly due to an increase in total surface area of lipid droplets, 
which has been suggested to increase the access of lipases to the lipid core. I 
investigated whether the turnover rate of TG is altered in OP9 cells when GX 
sPLA2 is overexpressed. By incorporating 3H-oleate into OP9 cells, I monitored 
the decay rate of the TG pool in OP9-GX and OP9-C cells. Unexpectedly, the 
starting point of 3H-oleate labeled TG pool was remarkably different between the 
two cell types. However, when normalized to baseline, the turnover rate of 3H-
oleate labeled TG was similar between OP9-C and OP9-GX. This data clearly 
indicated that the role of GX sPLA2 in reducing TG accumulation is not due its 
alteration in lipolysis. It is possible that the reduced lipolysis in the adipose tissue 
of GX-/- mice may be a secondary effect of increased TG accumulation and 
enlarged lipid droplets.  
I next investigated whether the rate of TG synthesis was altered in OP9-
GX. I have shown that OP9-GX had significantly reduced 3H-oleate incorporation 
into TG, which was not shown in inactive mutant expressing cells, OP9-H46Q. 
The incorporation of 3H-oleate incorporation into cholesterol ester (CE), 
diacylglycerol (DAG) or phosphatidylcholine (PC) was not affected in OP9-GX. It 
is clear from the data that GX sPLA2 negatively regulates TG accumulation in 
OP9 through reducing TG synthesis. Interestingly, this effect is dependent on its 
catalytic activity. In contrast to the results from the overexpression system, the 
addition of recombinant GX sPLA2 failed to have the same effect on TG synthesis 
in OP9 cells. As summarized previously, TG synthesis in adipocytes is regulated 
by various lipogenic enzymes, such as glycerol-3-phosphate acyltransferase 
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(GPAT), 1-acylglycerol-3-phosphate acyltransferase (AGPAT), phosphatidate 
phosphatase (PAP or lipin) and diacylglycerol transferase (DGAT). So far the only 
lipogenic gene I have tested in OP9 cells is DGAT1, whose expression was not 
significantly changed by GX sPLA2. Future experiments need to investigate 
whether other lipogenic genes are altered by GX sPLA2. In addition to mRNA 
expression, the specific activities of these enzymes should also be examined.  
Gene expression analysis during the differentiation of OP9-GX and OP9-C 
indicated that the overexpression of GX sPLA2 in OP9 cells led to suppressed 
induction of adipogenic genes, including peroxisome proliferator-activated 
receptor γ (PPAR γ), fatty-acid binding protein (FABP, aP2), sterol regulatory 
element binding protein-1c (SREBP-1c), fatty acid synthase (FAS) and stearoyl-
Coenzyme A desaturase 1 (SCD-1). Prior to differentiation, the expression of 
SREBP-1c was significantly lower in OP9-GX, but the expression of other genes 
was not significantly different between OP9-GX and OP9-C. After differentiation, 
all the listed genes were expressed significantly lower in OP9-GX. PPARγ, a 
member of the nuclear receptor family of ligand-activated receptors, is the master 
regulator of adipocyte differentiation [125-127]. PPARγ forms a heterodimer with 
the retinoid X receptor (RXR) to interact with PPARγ response elements (PPREs) 
on adipocyte-specific genes [132-133]. 3T3-L1 cells with PPARγ knockdown fail 
to differentiate into mature adipocytes, however, it was also shown that PPARγ 
was not required for the maintenance of mature adipocytes [134]. My finding 
suggests that the reduced TG accumulation in OP9-GX could be related to the 
reduced induction of PPARγ by overexpression of GX sPLA2 in OP9 cells. 
Possible mechanism may involve the hydrolytic product of GX sPLA2, especially 
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arachidonic acid (AA) and its metabolites, such as prostanoid, may inhibit the 
adipogenic program by suppressing PPARγ [253]. Another important role of 
PPARγ is to regulate insulin sensitivity. The well-known insulin sensitizer 
thiazolidinedione (TZD) is a high affinity ligand for PPARγ. Mouse with adipose 
tissue specific PPARγ deficiency exhibit led to severely reduced insulin sensitivity 
in adipose tissue and liver but not in the muscle [136]. Preliminary data from our 
laboratory showed reduced expression of glucose transporter GLUT4 expression 
in OP9-GX adipocytes. This also raises the interesting possibility that the 
reduced PPARγ expression in OP9-GX adipocytes may attribute to its reduced 
GLUT4 expression, thereby altering insulin sensitivity and glucose metabolism.  
Although PPARγ activation is critical for adipogenesis, accumulating 
evidence indicates that a number of other transcription factors can profoundly 
affect adipocyte differentiation, adipocyte-specific gene expression, and 
adipocyte lipid accumulation.  The genes being most significantly affected by GX 
sPLA2 were SREBP-1c, SCD1 and FAS, with around 70-80% of reduced 
expression. Interestingly, these genes were all shown to be target genes for LXR, 
a nuclear receptor critically involved in cholesterol, TG and glucose homeostasis. 
In recent years, LXR was shown to induce the expression of adipogenic 
/lipogenic program. LXR responsive elements (LXRE) was characterized in the 
promoter region of PPARγ and aP2, which linked LXR to adipogenesis [193, 195].  
T0901317, a synthetic LXR agonist, was shown to increase triglyceride TG 
accumulation in 3T3-L1 cells, and also induces the expression of adipogenic 
/lipogenic gene expression, including PPARγ, aP2, SREBP-1c and FAS[193]. 
Although the mechanism of LXR on adipogenesis remains to be identified, it is 
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accepted that activating LXR increases TG accumulation in adipocytes. LXRβ-/- 
mice were protected from diet or age-induced obesity [199-200, 254]. Studies in 
our laboratory have demonstrated that, in macrophages, GX sPLA2, regulates 
proinflammatory status by altering LXR activity. The effect of GX sPLA2 on 
suppressing LXR activation is possibly through its hydrolytic activity, which 
generates abundant release of arachidonic acid, thereby antagonizing LXR 
signaling. As described in Chapter 1, polyunsaturated fatty acid (PUFA), including 
AA is an antagonist of LXR activation. Two possible mechanisms may be 
involved in the antagonizing effect of PUFA on LXR activation 1) the competitive 
binding of PUFA on the ligand binding domain of LXR, thereby preventing the 
binding by LXR agonist [156] and 2) the interaction between AA and PPARs may 
activate PPARs [157-158], which in turn compete with LXR to bind on its 
heterodimer partner RXR.  
In my study, in order to examine whether GX sPLA2 regulates 
adipogenesis by altering LXR activation, I treated OP9-GX and OP9-C with 
T0901317 during differentiation. Consistent with a previously published study of 
3T3-L1 and primary human preadipocytes, LXR activation increased TG 
accumulation and adipogenic gene expression in OP9-C [193-194]. However, 
this effect was blunted in OP9-GX.  In order to directly examine the LXR 
promoter activity, OP9 cells were transiently transfected with mLXRα, LXRE 
luciferase construct, renilla, along with plasmids encoding GX sPLA2 or control 
expression vector. In the presence or absence of LXR agonist, the LXRE 
promoter activity was reduced in the cells overexpressing GX sPLA2. My data 
suggest that GX sPLA2 may negatively regulate adipogenesis through 
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antagonizing LXR activity. Possible mechanism involves the release of AA 
generated by the hydrolytic effect of GX sPLA2 (Fig 7.1). These findings are 
consistent with previously reported role of LXR in adipogenesis and the findings 
in macrophages and adrenal glands in our laboratory. Our laboratory has made 
the novel finding that GX sPLA2 negatively regulates corticorsteroid production in 
mouse adrenal cells. Possible mechanism is GX sPLA2 downregulates the 
expression of a rate-limiting enzyme, Steriogenic Acute Regulatory Protein 
(StAR), which was found to be a target gene of LXR [213]. Study in our laboratory 
has also shown that GX sPLA2 is expressed in macrophage and regulates the 
proinflammatory status of macrophages and proteins regulating cholesterol 
homeostasis (in revision). Peritoneal macrophages isolated from GX-/- mice have 
increased expression of ABCA1 and ABCG1, two key regulators of cholesterol 
efflux. Macrophage overexpressing GX sPLA2 have increased expression of 
inflammatory gene expression and the production of inflammatory cytokines after 
lipopolysaccharide (LPS) treatment. This interesting finding has implicated the 
potential impact on the inflammatory status of GX-/- mice. My preliminary data 
shows that GX-/- mice may have increased macrophage infiltration and increased 
inflammatory gene expression in the adipose tissue; however, the systemic 
inflammatory status of GX-/- mice need to be further examined. Obesity is known 
to be a chronic inflammation state, which leads to increased macrophage 
infiltration into the adipose tissues. In my preliminary studies, the increased 
adiposity and adipocyte hypertrophy may be associated with increased 
macrophage accumulation and inflammation in the adipose tissues. So it would 
be very important to investigate how GX sPLA2 may impact the cross-talk 
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between macrophage and adipocytes in adipose tissue, which may alter both 
local and systemic inflammation. The investigation into macrophage-derived GX 
sPLA2 in systemic inflammatory status and adipose tissue function will be 
achieved by bone marrow transplantation. 
In addition to its action on LXR activity, AA is also critically involved in 
various other physiological and pathological conditions. AA generated by the 
hydrolysis of extracellular or intracellular phospholipids by GX sPLA2 can be 
coupled to eicosanoid-generating enzymes cyclooxygenase (COX) isozymes 
COX-1 and COX-2, and 5-lipoxygenase, localized on perinuclear and 
endoplasmic reticular membranes [255]. The production of lipid mediators such 
as prostaglandins and lysophosphatidylcholine are known to have effects on 
adipose tissue [231, 256]. The release of hydrolytic products from lipoprotein 
particles should also be considered, given the potent ability of GX sPLA2 to act 
on HDL and LDL [43, 257]. Moreover, extracellular matrix (ECM) was also found 
to regulate adipogenesis as well as the expansion of adipose tissue in vivo [258]. 
Data from our laboratory has indicated that Group V (GV) sPLA2 may impact 
collagen deposition in the heart and aorta [259]. It is not known whether GX 
sPLA2 may also have similar effect on collagen deposition, which may also 
potentially impact on adipose tissue ECM, thereby regulating adipogenesis. 
Therefore, we cannot rule out the possibility that GX sPLA2 regulates 
adipogenesis by mechanisms independent of its effect on LXR. 
In summary, my findings indicate the hydrolytic activities of GX sPLA2 
participate in a vital role of TG homeostasis in murine adipocytes. Based on our 
finding, the mRNA level of GX sPLA2 in the adipose tissue did not appear to be 
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altered by high fat feeding (data not shown); however, it is not known whether the 
activity of GX sPLA2 in the adipose tissue is altered. Until now the mechanism by 
which the enzymatic activity of GX sPLA2 is regulated is not clearly understood. 
Findings in our laboratory and published report both indicate that the activity of 
GX sPLA2 may be increased during inflammation. Macrophage J774 cells 
overexpressing GX sPLA2 had increased enzymatic activity with 
lipopolysacharride (LPS) treatment. Obesity is now considered as chronic low-
grade inflammation, and high fat feeding induces the expression of inflammatory 
markers in the adipose tissues. It is possible that the activity of GX sPLA2 in the 
adipose tissue may be increased by high fat feeding, which further increased the 
effect of GX sPLA2 on adipogenesis. Due to the low renewal rate of adipocytes, 
in obesity, the failure to appropriately respond to the need to store excess energy 
in the form of TG may lead to metabolic disorders.  During nutrient overload, 
adipose tissue constantly expands in order to overcome the increased circulating 
plasma lipid, which is a protective mechanism to reduce lipotoxicity. GX-/- mice, 
by storing excess energy in the form of TG in adipose tissue, have reduced 
systemic inflammation, evidenced by improved insulin sensitivity. It is possible 
that GX sPLA2 acts as a checkpoint for TG accumulation in adipocytes.  
In mice, deficiency of GX sPLA2 led to increased body weight and 
adiposity, and studies in vitro provided possible mechanism by which GX sPLA2 
regulates adipogenesis; however, whether GX sPLA2 may impact the 
development of obesity in human remains to be clarified. Currently, little is known 
about the physiological role of GX sPLA2 in human. It was shown in the literature 
that human neutrophils express GX sPLA2 mRNA and contain GX sPLA2 proteins 
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[260]. In human macrophages, treatment of human GX sPLA2 recombinant 
protein led to activation of macrophage and cytokine secretion, which was shown 
to be dependent on M-type receptor binding and independent on its catalytic 
activity [45]. Future studies will also address the metabolic consequences of 
increased adiposity mediated by GX sPLA2 deficiency in mice, such as glucose 
homeostasis in liver and skeletal muscle as well as hepatic lipogenesis and 
gluconeogenesis. Additionally, our study is consistent with previously published 
work about the role of LXR activation in promoting adipogenesis and lipogenesis. 
Basic science has provided the encouraging evidence that LXR agonist 
treatment may be anti-inflammatory and atheroprotective. However, animal 
experiments have indicated the effect of synthetic LXR agonists may induce fatty 
liver by strongly upregulating hepatic lipogenic genes [186-187]. Due to the 
potential role of LXR in lipogenesis, the clinical use of LXR agonist needs to be 
cautiously examined. In order to minimize the side effect, tissue-specific LXR 
agonists for clinical treatment may be needed.  
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Figure 7.1 Model for GX sPLA2 regulating adipogenesis 
 
 
 
Cartoon modified from figure in the paper by Seo et al [193]. 
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